EXAMINATION OF Klebsiella pneumoniae 5’-METHYLTHIOADENOSINE/
S-ADENOSYLHOMOCYSTEINE NUCLEOSIDASE AND 5-METHYLTHIORIBOSE
KINASE

by
Jason Alan Stonick

A thesis
submitted in partial fulfillment
of the requirements for the degree of
Master of Science in Chemistry
Boise State University

May 2016

© 2016
Jason Alan Stonick
ALL RIGHTS RESERVED

BOISE STATE UNIVERSITY GRADUATE COLLEGE

DEFENSE COMMITTEE AND FINAL READING APPROVALS
of the thesis submitted by
Jason Alan Stonick
Thesis Title:

Examination of Klebsiella pneumoniae 5’-Methylthioadenosine/Sadenosylhomocysteine Nucleosidase and 5-Methylthioribose Kinase

Date of Final Oral Examination:

10 March 2016

The following individuals read and discussed the thesis submitted by student Jason Alan
Stonick, and they evaluated his presentation and response to questions during the final
oral examination. They found that the student passed the final oral examination.
Kenneth A. Cornell, Ph.D.

Chair, Supervisory Committee

Juliette Tinker, Ph.D.

Member, Supervisory Committee

Henry Charlier, Ph.D.

Member, Supervisory Committee

The final reading approval of the thesis was granted by Kenneth A. Cornell, Ph.D., Chair
of the Supervisory Committee. The thesis was approved for the Graduate College by
John R. Pelton, Ph.D., Dean of the Graduate College.

DEDICATION
This thesis is dedicated to my parents for supporting my education and taking the
statement “I’m moving to Boise next week” in due stride.

iv

ACKNOWLEDGEMENTS
I would like to first acknowledge Dr. Ken Cornell as my mentor and primary
resource during my research. I would also like to thank Dr. Juliette Tinker and Dr. Henry
Charlier for serving as my committee members. Additional thanks go to Dr. Steven Clegg
and Dr. Virginia Miller for kindly providing the K. pneumoniae strains I utilized in my
assays. I would also like to give my thanks to the Biomolecular Research Center and its
staff for funding me as a student and also being my laboratory home-away-from-home
when I needed a quiet place to get my work done. Dr. Danny Xu and Patrick Erstad both
contributed significantly to my research by performing molecular modeling of the MTRK
enzyme and small molecule screening for novel MTN inhibitors. Finally, I would like to
express my appreciation for the hard work of my fellow lab members, especially Kat
Dunlevy and Ally Isnor, for contributing their time and effort to the work included in this
thesis, and Necia Hunter for her laudable efforts to keep the lab space clean and
functional.
The project described was supported by the Idaho Beef Council and the
Institutional Development Awards (IDeA) from the National Institute of General Medical
Sciences of the National Institutes of Health under Grants #P20GM103408 and
#P20GM109095. We also acknowledge support from The Biomolecular Research Center
at Boise State with funding from the National Science Foundation, Grants #0619793 and
#0923535; the MJ Murdock Charitable Trust; and the Idaho State Board of Education.

v

ABSTRACT
Klebsiella pneumoniae is an opportunistic bacterial pathogen that is emerging as a
major global threat as an infectious agent. This organism, along with many other
pathogens, possesses a broad suite of antibiotic resistances that can make treatment
exceedingly difficult. As such, the impetus for creating novel antibiotics is at an all-time
high despite the fact that pharmaceutical investment into drug development is at an alltime low. S-adenosylmethionine (SAM) is a universally utilized metabolite involved in a
wide array of biosynthetic processes, and whose products are catabolized by a different
set of enzymes in mammals than used by many bacteria, protozoa, and plants. This
divergence provides two specific targets for enzymatic inhibition in K. pneumoniae: 5’Methylthioadenosine/S-adenosylhomocysteine

Nucleosidase

(MTN)

and

5-

Methylthioribose Kinase (MTRK). In order to examine the potential effects of drugs
targeting these enzymes, recombinant proteins from K. pneumoniae were isolated and
purified, and a profile of their respective kinetic activities were determined. The MTRK
enzyme was identified as using an ordered sequential mechanism, and shows preferential
binding towards substrate analogs with hydrophobic 5-alkylthio substitutions. In addition,
binding affinities of transition state-analogs and novel non-nucleoside small molecule
inhibitors of MTN were quantified. Finally, the effects of MTN inhibitors on K.
pneumoniae whole-cell growth, and gene expression were assessed. A number of the
inhibitors demonstrated strong affinities for the MTN enzyme and induced alterations in
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cellular growth, autoinducer response, and the expression of genes associated with
virulence.
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CHAPTER ONE: INTRODUCTION
Infectious Diseases
Microbial infections have been responsible for some of the most devastating
events in human history. The bubonic plague, smallpox, cholera, tuberculosis and
innumerable other infectious agents will forever be remembered because of the immense
impact they have had on human lives. It is no wonder, then, that the advent of antibiotic
drugs in the mid-20th century stands among the greatest of human achievements.
However, the efficacy of drug treatments have universally waned from the moment of
their introduction. Resistance mechanisms towards new antibiotics have inevitably
sprung forth after their use in the market, often in the span of just a few short years
(Figure 1.1).

Figure 1.1. Timeline of antibiotic use and appearance of drug resistance. Adapted
from Clatworthy, et al., 2007.
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The short efficacious lifespan of new antimicrobials has disincentivized
pharmaceutical companies from investing resources in further antibiotic research and
development. This has led to a critical decline in the number of new treatments available,
while the prevalence of antibiotic-resistant organisms steadily rises (Spellberg, et al.,
2004). Current trends suggest we are moving towards the emergence of a so-called “postantibiotic” era, in which we will once again lack the means to medically treat infections
(WHO, 2015). The implications of this are drastic considering approximately 720,000
nosocomial infections and 75,000 resultant deaths occur every year in the United States
alone (Magill, et al., 2014). Globally, 90 million people contracted malaria and 2.6
million contracted pneumonia in 2014 (WHO, 2014). In fact, mortality from infectious
and parasitic diseases accounts for 19.1% of global deaths, even in our current pre-“postantibiotic” world (WHO, 2004).
As such, a new class of antimicrobial drugs would be more valuable now than at
any time since prior to the discovery of penicillin. However, in view of the rate of
evolutionary acquisition of resistance, it is critical that efforts be made to limit the ability
for pathogens to quickly develop a means of subverting a drug’s mode of action. Modern
thinking asserts that molecules that interfere with microbial pathogenicity rather than
survival will reduce the selective pressure that leads to antibiotic resistance, and allow
natural immunity to fight off an infection. Therefore, drugs that are designed with these
precepts should be capable of preventing or delaying the emergence of drug resistance.
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Klebsiella pneumoniae
Classification and Threat
Klebsiella pneumoniae is a Gram-negative rod shaped bacteria in the
Enterobactericeae family. While part of the normal flora of the human body, various
strains possess high pathogenic capacity, especially while acting as a nosocomial agent
and towards people with pre-existing conditions resulting in compromised immune
systems (e.g. diabetes, alcoholism, HIV, etc.). Its modes of pathogenicity allow it to
clinically manifest as urinary tract infections, pneumonia, septicemia and soft tissue
infections. Klebsiella pneumoniae accounts for 3-7% of hospital-associated bacterial
infections (Podschun, et al., 1998), placing it among the eight most prevalent infectious
pathogens. However, the greatest concern towards K. pneumoniae is due to the drug
resistance profile of many clinical isolates. Pathogenic strains often carry plasmid-born
resistances, and K. pneumoniae was among the first organisms found to possess genes for
aminoglycoside resistance and extended-spectrum β-lactamase (ESBL) activity, which
confers resistance to cephalosporins and aztreonam (Arnold, et al., 2011).
In the early 1990’s, a novel β-lactamase was found in Klebsiella, termed
“Klebsiella pneumoniae carbapenemase” (KPC). KPC confers resistance to virtually all
β-lactam drugs, including penicillins, cephalosporins, monobactams, and carbapenems
(Arnold, et al., 2011). This was a critical development as carbapenems are a class of drug
with regulated medical use as a “last resort” treatment for Gram-negative bacterial
infections in order to preserve their efficacy and longevity. The KPC gene proved to be
highly mobile and spread rapidly among other Gram-negative species, creating a class of
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organisms known as “carbapenem-resistant Enterobactericeae” (CRE). The KPC gene is
now the most commonly found carbapenemase gene worldwide (Nordmann, et al., 2009).
In 2009, a new carbapenemase gene with a novel mode of action was isolated
from K. pneumoniae (Yong, et al., 2009). Named the “New Delhi metallo-β-lactamase”,
this gene is also rapidly spreading across the globe and among other Gram-negative
bacteria such as E. coli, Enterobacter cloacae, and Salmonella enterica. A survey of New
Delhi carbapenemase-bearing clinical isolates in the U.S. showed that all of them also
possessed

resistance

to

additional

antibiotics

including

aminoglycosides

and

fluoroquinolones, and also possessed one or more alternate β–lactamases (Rasheed, et al.,
2013). Due to difficulty of treatment, CRE organisms are significantly more virulent,
with mortality rates for septic patients at 71.9% vs. 21.9% for non-CRE infections (Borer,
et al., 2009). The rate of occurrence is also increasing, with the proportion of CRE
infections accelerating from 0.6% to 5.6% during 2004-2008 (Gupta, et al., 2011). K.
pneumoniae currently poses a major threat to the medical community and is poised to
become an even greater danger in the near future.
Pathogenic strains of K. pneumoniae possesses a suite of traits that help to enable
their capacity for infection and morbidity, which include: mucoviscosity, cellular
adhesion, biofilms, and siderophores.
Mucoviscosity
High mucoviscosity, often referred to as hypermucoviscosity, is a common
characteristic of many infectious strains of K. pneumoniae. Manifesting as an
extraordinarily thick accumulation of extracellular capsular polysaccharide (CPS)
surrounding the cells. Positive strains can be readily identified by a “stringiness” of the
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colonies (Figure 1.2). The capsule serves as a physical buffer that helps exaggerate
bacterial defense mechanisms.

Figure 1.2. Hypermucoviscous Klebsiella pneumoniae. This positive stretch test of a
hypermucoviscous strain shows the characteristic stretch of a mucoid colony. (Shon, et
al., 2013).
The hypermucoviscosity trait strengthens defense against host immune responses
and contributes significantly to host mortality during infection. K. pneumoniae strains of
the K1 and K2 serotypes most highly associated with hypermucoviscosity express an
estimated 15-17 genes implicated in upregulation of CPS synthesis (Wu, et al., 2009;
Arakawa, et al., 1995). Of these, the magA gene (K1 strains), confers complete resistance
to bactericidal human serum and a greater than 105-fold decrease to the lethal dose in
mice (Fang, et al., 2004). High capsule production in both serotypes are reported to
confer resistance to opsonin-dependent phagocytosis by human neutrophils (Domenico,
et al., 1994). Non-capsule forming K. pneumoniae mutants showed drastically reduced
virulence in mouse pulmonary infections (Chhibber, et al., 2003). These findings
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highlight the importance of capsule production as a virulence factor in K. pneumoniae
infections.
Cellular Adhesion
Many pathogenic strains of K. pneumoniae possess the ability to bind to the
surface biomolecules of mammalian cells. This is achieved largely through the action of
extracellular structures referred to as pili or fimbriae. These long, thin columnar
structures protrude from the cell membrane through the capsular layer and facilitate
binding to extracellular matrix proteins and cell surface markers (Proft, et al., 2009).
Pathogenic K. pneumoniae genomes encode two distinct adhesive fimbriae, designated as
type 1 and type 3. Type 1 fimbriae are characterized by their capacity to agglutinate
guinea pig erythrocytes (Figure 1.3). They are also responsible for adhesion to human
bladder and tracheal cells (Fader, et al., 1979; Fader, et al., 1988). In contrast, type 3

Figure 1.3. Structure of a type 1 fimbriae. The main body is comprised of a helix of
repeating subunits and is capped by a single adhesive subunit. Fimbriae can range in
length from 1 to 2 µm. (Adapted from Bodelon, et al., 2013.)
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fimbriae are characterized by their ability to only agglutinate tannin-treated erythrocytes,
and enable adhesion to respiratory tissues (Hornick, et al., 1992). These fimbriae also
confer bacterial adherence towards plastic surfaces (Jagnow, et al., 2003) and the
ubiquitously expressed extracellular matrix proteins (collagen, fibrinogen, and
fibronectin) found in epithelial tissues (Hennequin, et al., 2007).
Multiple plasmid-borne adhesive factors also exist in K. pneumoniae. The
adhesive factor CF29K was acquired from other enteropathogens, and mediates binding
to gastrointestinal tissues (Martino, et al., 1995). Interestingly, high capsule production
antagonizes tissue adherence. This is proposed to occur by blocking adhesive factor
accessibility due to excess capsule (Schembri, et al., 2005). Tissue specific
downregulation of capsule production may act as an early adaptive response that
facilitates bacterial adherence at the site of infection (Vartivarian, et al., 1993).
Subsequent upregulation of capsule production may later improve virulence by protecting
the pathogen from host immune responses.
Biofilms
Recent studies indicate that the many decades of research examining in vitro
bacterial cultures may have focused on a mostly irrelevant planktonic growth phase.
Under natural growth conditions, bacteria more often form complex microbial
communities called biofilms. These colonies are formed from extracellular secretions of
carbohydrates, proteins and DNA that form a dense connective network that enmeshes
the cells together (Figure 1.4). Bacterial behavior within these structures is highly
modified, displaying functions that are not observed in free planktonic growth. Cells
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growing within biofilms are known to undergo an alteration in their expression of surface
markers, nutrient metabolism, and in their virulence profiles (Schembri, et al., 2003).

Figure 1.4. Extracellular components of biofilms. Biofilm deposition is facilitated
by bacterial adhesins and flagella. The polymeric matrix is composed mostly of structural
polymers like colonic acid, cellulose, polyglucosamine (PGA), and extracellular DNA
(eDNA) (Kostakioti, et al., 2013).
Biofilm formation is initiated by cellular adhesion to either living tissue or abiotic
surfaces, especially in response to adhesion by type 1 fimbriae (Pratt et al., 1998).
Plastics are particularly prone to biofilm formation, contributing heavily to the incidence
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of catheter-related urinary tract infections (Trautner & Darouiche, 2004). Following
initial bacterial adhesion, various extracellular biofilm constituents are secreted. The
composition of these secreted molecules are dictated heavily by environmental factors
(Harmsen, et al., 2010). Biofilm formation is found to be highly dependent on expression
of the type-3 fimbriae subunit MrkA in K. pneumoniae (Schroll, et al., 2010). Biofilms
permit the accumulation of Autoinducer (AI) signaling molecules and the second
messenger, 3,5-cyclic diguanylic acid (c-di-GMP), which induce alterations in gene
expression to promote biofilm maturation and expansion (Kostakioti, et al., 2013).
Compared to free-living organisms, microbes within biofilms possess traits that
enable environmental survival and are therefore more likely to cause clinical disease. The
inherent hydrophilicity of polysaccharides produces a “slime” that helps prevent cell
desiccation, and the physical nature of biofilms results in resistance to removal from
surfaces by shear forces. Cells cloistered within biofilms are also physically protected
from human immune responses (Jesaitis, et al., 2003). Poor diffusional properties within
these biomaterials, combined with metabolic changes that are not fully characterized
result in an upwards of 500-fold increase in antibiotic resistances (Costerton, et al.,
1995).
Even more pernicious is the existence of internal “persister” cells. These deeply
embedded cells experience an environment of nutrient and oxygen deprivation that
induces a state of metabolic stasis. The cessation of nearly all molecular activity grants
inherent insensitivity towards many antibiotics. However, persister cell activity can be
resumed following the death of nearby non-persister cells in response to antibiotic
treatment (Lewis, 2005). As a result, biofilm-associated infections often require surgical
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removal of affected tissues to prevent chronic recurrence. The co-localization and
concentration of cell populations in biofilms have also been found to expedite lateral
gene transfer, facilitating the spread of plasmid-borne drug resistances and virulence
factors (Flemming, & Wingender, 2010).
Siderophores
Siderophores comprise a class of secreted small molecules that act as metal ion
chelators and are used primarily to scavenge iron from the environment and import it into
the cell. Iron is a vital component of enzymes involved in many cellular processes,
including respiration and DNA synthesis. The vast majority of iron in humans is
sequestered within hemoglobin, ferritin, and transferrin, leaving a free Fe3+ ion
concentration of approximately 10-24 M (Vasil, & Ochsner, 1999). However, optimal
growth conditions for microorganisms require roughly 1 µM of iron, requiring a means of
extracting host iron to enable efficient proliferation by pathogens (Miethke, et al., 2008).
There are dozens of physically distinct siderophores produced by Gram-negative bacteria,
with no discernable conservation of type utilized, even by closely related species. A
survey of 475 K. pneumoniae strains showed 98.8% produced siderophores (Podschun, et
al., 1992) with aerobactin being the most relevant form utilized during infection (Russo,
et al., 2015). Previous research has shown that genetic knock-outs of siderophore genes in
K. pneumoniae produce avirulent strains (Hsieh, et al., 2008), thus identifying
siderophores as a requisite component of pathogenicity. The rmpA gene, one of the most
widely shared enhancers of CPS among K. pneumoniae strains, has been reported to be
downregulated at high iron concentrations (Cheng, et al., 2010). Potentially, siderophore-
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mediated loss of capsule synthesis may improve the ability of the organism to establish
new sites of colonization during a septic infection.

Figure 1.5. Structural diversity of bacterial siderophores. Iron chelating groups are
highlighted and color coded by common structure. (Adapted from Miethke & Marahiel,
2007.)
5’-Methylthioadenosine/S-adenosylhomocysteine Nucleosidase
Function and Prevalence
S-adenosylmethionine (SAM or AdoMet) is one of the most widely used
molecules in biochemical pathways and is the second most utilized enzymatic substrate
after ATP (Fontecave, et al., 2004). Four of the most critical SAM functions are

Figure 1.6. Depiction of substrate-bound E. coli MTN. Ribbon diagram of the MTN
enzyme co-crystallized as a native homodimer with two bound non-hydrolyzable MTA
analog molecules in the active sites (Lee, at al., 2001; PDB: 1NC1).
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transmethylation reactions, bacterial autoinducer production, polyamine synthesis, and
radical SAM reactions. The enzyme 5’-methylthioadenosine/S-adenosylhomocysteine
nucleosidase (known as MTN, mtnN, or MTAN) is responsible for the irreversible
depurination of several metabolic products of SAM-dependent reactions by addition of a
water molecule. MTN is a functional homodimer with each unit mutually forming part of
two symmetric binding sites (Figure 1.6). Bacterial MTN catalyzes the breakdown of
three known substrates: 5’-methylthioadenosine (MTA), S-adenosylhomocysteine (SAH),
and 5’-deoxyadenosine (5’dADO). The products of MTN reactions are recycled via
purine and methionine salvage pathways (Figure 1.7). In mammals, the analogous
enzyme activities are performed by two different enzymes: 5’-methylthioadenosine
phosphorylase (MTAP) and S-adenosylhomocysteine hydrolase (SAHH). MTAP is a
homotrimer with similar but not identical binding site properties to MTN, and catalyzes
the reversible phosphorylytic depurination of MTA. SAHH is evolutionarily distinct and
does not deadenylate the substrate SAH. Instead it resembles an enzymatic class of NADdependent hydrogenases and cleaves the 5’ carbon-sulfur bond of SAH to yield adenosine
and homocysteine using an NADH cofactor (Turner, et al., 2000).
The buildup of MTA and SAH are both toxic to cells (Christa, et al., 1988) and
strong product inhibitors of the pathways that form them (Parveen & Cornell, 2011). As a
result of the expansive number of enzymes involved in radical SAM reactions there is
still an incomplete profile of the consequences of 5’dADO buildup. However, it also has
been characterized as a product inhibitor for some of its dependent enzymes, such as
biotin and lipoyl synthases (Choi-Rhee & Cronan, 2005).
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Bacterial MTN facilitates the deadenylation of three distinct products of Sadenosylmethionine (SAM) dependent reactions.
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The accumulation of these three nucleosides as a result of MTN inhibition is
therefore expected to act as a powerful means of debilitating a multitude of biochemical
pathways. Despite the central role of MTN in these diverse metabolic functions, it is not
strictly required for cellular survival. MTN gene knock-out strains (MTN KOs) of
Staphylococcus aureus and Neisseria meningitides grew normally in nutrient replete
media, but showed reduced virulence (Bao, et al., 2013; Heurlier, et al., 2009). MTN KO
strains of E. coli (RK4353, O157:H7) showed reduced growth rates, altered metabolism,
and decreased toxin production (Knippel, 2013). This supports a role for MTN in the
promotion of organismal growth and the expression of virulence factors instead of cell
survival. As a result, targeting MTN with chemotherapeutics should enable the host
immune system to more effectively cope with infection, placing the drugs themselves
under less selective pressure for the development of antibiotic resistance (Clatworthy, et
al., 2007). The MTN enzyme is relatively well conserved among bacteria, being found in
51 of 138 bacterial species examined (Parveen & Cornell, 2011) and is also utilized by
various parasites, such as Entamoeba histolytica (Larson, et al., 2010) and Giardia
lamblia (Riscoe, et al., 1988). MTN is also found in most plant species, where it plays a
role in synthesis of the hormone ethylene (Kushad, et al., 1985). The broad organismal
utilization of MTN could allow a potent MTN inhibitor to act as a broad-spectrum
antimicrobial against a diverse array of organisms.
Previous efforts at designing inhibitors for MTN have largely consisted of
attempts to create molecules that act as either early or late-stage transition state analogs
(TSAs). The underlying principle is that enzymes function by stabilizing an energetically
unfavorable intermediate transition between the reactants and products. Thus, the affinity
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of the enzyme towards molecules resembling that intermediate state are theorized to
exceed that of the natural substrates by a factor equal to the rate of catalytic acceleration
(Wolfenden, et al., 2001). The mechanism of MTN during catalysis is initiated by the
protonation of N7 of the adenyl group, followed by a donation of electron density from
the ribose ring oxygen and SN1-type dissociation of the purine from the ribose.
Afterwards, a localized water molecule attaches to the resultant highly reactive
ribooxacarbenium ion (Figure 1.8). Efforts have thus centered around modifying electron
density and bond length properties on the 1’ carbon, examining the influence of 5’
alkylthio substitutions, and utilizing a non-hydrolyzable glycosidic bond to prevent the
drugs from enzymatic degradation.
Efforts to create TSA inhibitors of bacterial MTN have been remarkably
successful. Dissociation constants for some late-stage TSA inhibitors have been as low as
47 femtomolar against E. coli MTN, which represents a 91 million-fold greater binding
affinity than for the substrate SAH (Singh, et al., 2005). These inhibitors represent some
of the tightest binding non-covalent inhibitors for any known enzyme. Unfortunately,
their observed effects on cellular behavior have typically been less dramatic. V. cholerae
growth in media supplemented with a TSA inhibitor at a million-fold concentration
greater than the Ki failed to affect growth (Schramm, et al., 2008).
However, TSA drugs applied even at picomolar concentrations were found to
disrupt autoinducer-2 and biofilm formation in both V. cholerae and E. coli (Gutierrez, et
al., 2009). More recently, ten different MTN inhibitors were discovered to significantly
reduce growth in Helicobacter pylori and are being examined as species-specific
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Figure 1.8. Rationale for MTN transition-state analog design. A) Representation of
MTN catalysis of 5’-methylthioadenosine to 5-methylthioribose and adenine. B)
Examples of both early and late-stage transition state inhibitors. Both possess nonhydrolyzable bonds on the equivalent of the 1’ carbon, with bond elongation in the latestage analog. Early onset (unmarked) inhibition values were derived from initial enzyme
velocities. Delayed-onset (*) inhibition values are derived from the kinetic rates
following thermodynamic equilibrium of the drug-enzyme complex (data from Singh, et
al., 2005).
antibiotics (Wang, et al., 2015). To date, no data regarding MTN inhibitor effects on K.
pneumoniae growth have been published.
In order to be useful as chemotherapeutic agents, MTN inhibitors should
demonstrate little to no effect on human cells. MTAP is the mammalian enzyme with
greatest homology to MTN, and thus with the greatest concern for unintended inhibition.

17
While MTAP also acts on the substrate MTA, it uses a different nucleophile (phosphate)
to effect a reversible cleavage of the glycosidic bond to generate adenine and MTR-1phosphate. Though similar to MTN in function, the differences in active sites are drastic
enough to allow the design of molecules that preferentially inhibit MTN without
significantly affecting MTAP (Longshaw, et al., 2010). In particular, the clustering of
positively charged amino acids near the ribosyl 2’ carbon for MTAP, and its more
occluded binding site near the 5’ carbon have been proposed as exploitable differences
for drug design (Lee, et al., 2003). An extensive analysis of TSA inhibitors have shown
up to a 1300-fold binding discrimination favoring MTN over MTAP (Longshaw, et al.,
2010).
A broad variety of extremely powerful transition state analog inhibitors of the
MTN enzyme have been identified. Due to MTN’s diverse role in multiple metabolic
pathways, enzymatic inhibition of this enzyme is expected to induce changes the
metabolic processes involved in transmethylations, the production of autoinducers and
polyamines, radical SAM reactions contributing to vitamin and cofactor synthesis, and
methionine salvage.
Activated Methyl Cycle
Transmethylations are a ubiquitously utilized biological process. Methyl
recipients include most main classes of biomolecules: phospholipids, proteins, nucleic
acids, carbohydrates, and some small molecules like catechol and glycine. More than
twenty distinct SAM-dependent methyltransferases have been identified (Chiang, et al.,
1996). DNA methylation is the most studied function of methyltransferases, where the
cytosine residues in CpG motifs are methylated to regulate histone association and mark
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cell cycle progression (Cheng, et al., 2001). Additional methyl recipients include rRNA
(Vester & Long, 2009), tRNA (Urbonavicius, et al., 2005), proteins that affect enzymatic
activity and influence signal transduction, and L-rhamnose sugars, which are methylated
before incorporation into the glycan chains in bacterial cell walls (Steiner, et al., 2008).
While the complete role of phospholipid methylation is still debated, it is known to
function as an alternate synthetic method for creating phosphatidylcholine (Chiang, et al.,
1996). A summary of known methyl recipient molecules and the processes that are
affected are shown in Table 1.1.
Table 1.1.

Effects of molecular methylation, by acceptor type.

DNA
Protein
Lipids
Carbohydrates
Small molecules

Gene repression, genome imprinting, replication timing,
development, DNA repair
Protein function (via charge, orientation, hydrophobicity, etc.),
signal transduction, chemotaxis, growth phase regulation
Phosphatidylcholine synthesis, calcium transport, adenylate
cyclase activation, signal transduction
Glycan formation
Neurotransmitter degradation, amino acid synthesis

SAM is the most common methyl group donor, and the product of these reactions
is SAH (Figure 1.9). Transmethylation reactions are subject to product inhibition by SAH
at low micromolar concentrations (Caudill, et al., 2001).

Figure 1.9. Mechanism of general SAM-dependent methyltransferase activity.
SAM represents the most widely utilized source of methyl donor groups.
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Autoinducer Production
Autoinducers (AIs) are a class of small molecules utilized by single-celled
organisms as a means of coordinating group behavior in a process known as “quorum
sensing”. First discovered in V. fischeri and V. harveyi, autoinducer signaling was
responsible for stimulating bioluminescence in response to high cellular concentration
(Kaplan & Greenberg, 1985). Later studies discovered quorum sensing was a mechanism
utilized by a large number of Gram-positive and Gram-negative bacteria. Processes
influenced by quorum sensing include bioluminescence, spore formation, biofilm
development, and virulence factor secretion (Rutherford, et al., 2012). Most Gramnegative bacteria are capable of producing two distinct forms of autoinducers, AI-1 and
AI-2.
AI-1 is formed from the methionyl group of SAM that spontaneously cyclizes
upon addition of a hydrocarbon chain from acyl-carrier protein (ACP). The acyl chain
length varies between bacteria and is thereby considered to be a form of species-specific
communication. AI-2 is formed by isomerization of the ribose moiety of Sribosylhomocysteine (SRH) to 4,5-dihydroxy-2,3-pentanedione (DPD). In aqueous
environments, DPD cyclizes and forms a complex with aqueous boric acid (Figure 1.10).
AI-2 is invariant among species and thought to act as a universal quorum sensing
molecule. As AI-2 synthesis is dependent on a product of MTN metabolism and AI-1 is
subject to feedback inhibition by MTA, both signaling pathways are highly dependent on
nucleosidase activity.
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Figure 1.10. Synthetic pathways of Autoinducers 1 and 2. A) Production of AI-1
from SAM and acyl carrier-protein. The reaction is mediated by LasI and creates an acyl
homo-serine lactone with a hydrocarbon chain length that varies depending upon the
species. B) Synthesis of AI-2 from S-ribosylhomocysteine, as mediated by LuxS. This
reaction creates 4,5-dihydroxy-2,3-pentadione (DPD). DPD spontaneously cyclizes to the
precursor molecule 1-deoxy-3-dehydro-D-ribulose (pro-AI-2), which exists in
equilibrium with an active borate diester form (AI-2).
K. pneumoniae lacks the AHL synthase enzymes required to create AI-1 and
relies solely on AI-2. AI-2 deficient mutants of the LuxS gene in K. pneumoniae
displayed structural impairments in early biofilm formation (Balestrino, et al., 2005). K.
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pneumoniae knock-out strains for AI-2 transport proteins were also shown to have an
increase in the production of extracellular lipopolysaccharides (Araujo, et al., 2010).
Polyamine synthesis
Polyamines are small organic polycations utilized by all forms of life and are
considered as an element of the minimal metabolome of cells (Lee, et al., 2009). The
positive charges enable interactions with negatively charged molecules like DNA,
proteins, and cell wall components. In bacteria, polyamines are known to play a role in
DNA replication, transcription, translation, cellular growth, siderophore synthesis,
swarming, and biofilm formation (Lee, et al., 2009). Regulation of apoptosis is also
known to be under partial control by polyamines (Seiler & Raul, 2005). There are four
major polyamines synthesized in most organisms: putrescine, spermidine, spermine and
cadaverine. Among bacteria, spermine and cadaverine are often synthesized only in trace
amounts. Many bacteria, including K. pneumoniae, are incapable of synthesizing
spermine. In contrast, putrescine and spermidine are heavily utilized, with intracellular
concentrations typically in the low millimolar range (Shah & Swiatlo, 2008). The
biosynthetic pathway for polyamines is initiated by the formation of putrescine from
either L-ornithine or L-arginine. Both spermidine and spermine are synthesized by the
addition of a propylamine group from decarboxylated SAM to putrescine and spermidine,
respectively (Figure 1.11). These events are catalyzed by spermidine and spermine
synthases and form MTA as a byproduct. Cadaverine is synthesized through an
independent mechanism, in which L-lysine is converted to cadaverine directly by lysine
decarboxylase. MTA acts as a product inhibitor of both spermidine and spermine
synthases (Pajula & Raina, 1979; Evans, et al., 2004).
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Figure 1.11. Spermidine synthesis. Formation of spermidine from putrescine and
decarboxylated S-adenosylmethionine (dcSAM) via the spermidine synthase enzyme.
The addition of a second aminopropyl group from dcSAM to spermidine by spermine
synthase produces the polyamine spermine. Spermine is not usually synthesized de novo
in bacteria, but can be formed in the presence of exogenous spermidine (Shaw & Swiatlo,
2008).
Radical SAM syntheses
Radical SAM enzymes constitute a recently discovered superfamily whose
function is dependent on a conserved CxxxCxxC amino acid domain, with a nonconserved fourth cysteine contributing to a catalytic [4Fe-4S] cluster (Challand, et al.,
2009). Radical SAM functions encompass more than 40 distinct synthetic processes with
a conserved mechanism by which the iron-sulfur cluster facilitates the removal of
methionine from SAM to produce a 5’-deoxyadenosine radical (Figure 1.12). The radical
is quickly transferred to either another substrate or onto the SAM radical enzyme by the
abstraction of a hydrogen atom. Some functions of SAM radical enzymes include: DNA

Figure 1.12. The general mechanism of radical formation and transfer by SAM
radical enzymes. The 5’-deoxyadenosine radical species transfers the radical electron by
the abstraction of a hydride group from the target small molecule or enzyme.
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repair, anaerobic DNA metabolism, lipoyl production, and the synthesis of the cofactors
pyrroloquinoline quinone, biotin, and thiamine (Frey, et al., 2008). Thiamine (vitamin B1)
is an essential cofactor in the central carbon metabolism of both glucose and pentose
sugars (Figure 1.13). Thiamine deficiency is known to cause significant defects in
cellular proliferation (Gigliobianco, et al., 2010). The radical SAM enzymes biotin
synthase, lipoyl synthase, thiamine synthase, and tyrosine lyase are all subject to product
inhibition by a combination of 5’dADO and methionine (Challand, et al., 2009).

Figure 1.13. The role of thiamine as a cofactor in central carbon metabolism.
Thiamine is crucial for the function of enzymes involved in glycolysis, the citric acid
cycle, and the pentose phosphate pathway. (Adapted from Harrigan, et al., 2008.)
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Methionine salvage pathway enzymes – 5-methylthioribose kinase (MTRK)
5-Methylthioribose Kinase
Methionine recycling is intertwined with all three MTN substrates. MTRK is the
enzyme responsible for initiating methionine salvage from 5-methylthioribose (MTR),
the product of MTA depurination by MTN. MTRK facilitates the phosphate transfer from
ATP to carbon-1 of MTR (Figure 1.14). Unlike MTN, the MTRK enzyme is utilized by a
much more restricted group of bacteria (Klebsiella, Bacillus, Rhizobium, etc.). MTRK is
also broadly present in plants but is absent in mammals, suggesting it could be a good
target for species-specific antibiotic or herbicide development.
The methionine salvage pathway (Figure 1.14) begins with MTA produced from
SAM-dependent polyamine or AI-1 synthesis. MTN depurinates MTA to produce
adenine and MTR. MTRK then catalyzes the phosphotransfer reaction from ATP to MTR
to produce 5-methylthioribose-1-phosphate (MTR-1P). In K. pneumoniae, the remainder
of the pathway is as follows: MTR-1P undergoes isomerization to methylthioribulose-1phosphate, and is subsequently dehydrogenated to 2,3-diketo-methylthiopentane-1phosphate. This is then dephosphorylated to 1,2-dihydroxy-3-keto-5-methylthiopentene,
which is then oxidatively decarboxylated to 2-keto-4-methylthiobutyrate (KMTB).
KMTB is then selectively transaminated to reform methionine.
This process is adhered to by many organisms, with slight variations among
species. Methionine is also a product of radical SAM reactions and can be recycled from
homocysteine, a product of SAH breakdown. The recycling of methionine is an important
function, as the molecule is energetically costly to synthesize de novo. Many
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Figure 1.14. Methionine salvage cycle in Klebsiella pneumoniae. The activity of the
alternative mammalian MTAP pathway is denoted by a dashed line.
organisms lack synthetic enzymes to create methionine, and rely upon the salvage
pathways to conserve this amino acid (Albers, 2009). As MTRK is not utilized by
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mammals, it has undergone investigation as a potential target of antibiotic development.
A large number of MTR analogs with substitutions of the 5-alkylthio moiety have proved
successful in inhibiting MTRK activity. Substituted 5-phenylthioribose analogs in
particular have demonstrated strong effects on K. pneumoniae growth, the most potent of
which displayed an IC50 value of 2.5 picomolar (Winter, et al., 1993). The analogs 5trifluoromethylthioribose (TFMTR) and 5-ethylthioribose (ETR) have been demonstrated
to act as catalyzable substrates and continue through downstream metabolism to produce
the toxic molecules of carbonothioic difluoride (thiophosgene gas) and ethionine,
respectively (Gianotti, et al., 1990; Tower, et al., 1991; Winter, et al., 1993). The broad
acceptance of MTR analogs as either functional inhibitors or accepted substrates shows
an high degree of substrate promiscuity which may provide opportunities for exploitation
in future drug designs.
Summary
The bacterial organism Klebsiella pneumoniae acts as an important nosocomial
pathogen and is poised to become an even greater threat in the near future. K.
pneumoniae possesses two enzymes, 5’-methylthioadenosine nucleosidase (MTN) and 5methylthioribose kinase (MTRK), which are not found in humans. These enzymes
contribute to many important metabolic functions, which include: transmethylations,
autoinducer synthesis, polyamine production, radical SAM reactions, and the salvage of
methionine. As a result, MTN and MTRK have been identified as targets for the
development of novel antimicrobial therapeutics. The research presented here consists
largely of efforts following the purification of these two enzymes from genes cloned and
expressed from the K. pneumoniae genome. Chapter 2 (pg. 27) presents a manuscript
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derived from the characterization of the kinetic properties, substrate affinity, and kinetic
mechanism of the MTRK enzyme. Chapter 3 (pg. 46) reports a manuscript based on
investigations into MTN regarding kinetics towards the three unique substrates, and the
determination of inhibition constants for several transition state analog and novel nonnucleoside small molecule inhibitors. Chapter 4 (pg. 61) contains research towards a third
publication that investigates the in vitro effects of MTN inhibitors against K. pneumoniae
regarding growth, biofilm formation, autoinducer-2 secretion, and the transcriptional
expression of multiple virulence factors.
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CHAPTER 2: PAPER #1 – CHARACTERIZATION OF Klebsiella pneumoniae 5METHYLTHIORIBOSE KINASE
Abstract
5-Methylthioribose kinase (MTRK) is an enzyme unique to the methionine
salvage pathway of plants and some microbes. The MTRK enzyme catalyzes the
phosphorylation of 5-methylthioribose (MTR), a product of the synthesis of polyamines,
autoinducer-1, and ethylene, in order to initiate the methionine salvage pathway. The
absence of MTRK in mammals has established this enzyme as a potential target for the
development of novel antibiotics. Analysis of genomic data for MTRK reveals a high
degree of sequence homology between diverse organisms, and suggests the presence of
both methionine and purine-dependent regulatory elements for MTRK gene expression in
the nosocomial pathogen Klebsiella pneumoniae. A K. pneumoniae recombinant MTRK
enzyme was cloned and purified and the Km values for MTR and ATP were found to be
21 ± 2 and 70 ± 10 µM respectively, with a specific activity of 6.2 ± 0.2 µmol/min per
mg. Investigation into substrate acceptance of MTR analogs with substitutions at the 5carbon position demonstrated a high affinity towards groups with hydrophobic properties.
Product inhibition studies using MTR-1-phosphate (MTR-1P) suggest an ordered
sequential reaction mechanism with ATP binding first and MTR-1P being the first
product released.
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Introduction
Methionine salvage is important for the recycling of methionine utilized in Sadenosylmethionine (SAM) dependent methylation reactions, polyamine synthesis, and
the radical SAM reactions involved in vitamin biosynthesis [8, 21, 26]. Recovery of
methionine from MTA is a highly conserved function [26], as the de novo synthesis of
methionine is considered to be energetically “costly”. Indeed, many organisms lack de
novo methionine synthetic pathways entirely and instead rely solely on exogenous
sources and salvage methods. The utilization of the MTRK enzyme is common among
plants but highly unusual among bacterial species. Of note among these are the genus
Serratia, Enterobacter, and Klebsiella. These organisms act as common nosocomial
agents with significant clinical impacts. The absence of MTRK in mammals and the
majority of bacterial species provides an opportunity for the development of targeted
antibiotics that would not disturb the human microbiome.
The MTRK enzyme is a functional homodimer with a structural homology to the
choline/ethanolamine kinase enzyme family [17]. It is responsible for committing the
waste product 5-methylthioribose (MTR) to the salvage pathway by phosphorylation at
the 1-carbon position, at the expense of ATP. The methionine salvage pathway itself
(Figure 2.1) is initiated following the addition of methionine to ATP, which produces Sadenosylmethionine (SAM or AdoMet). SAM is utilized in an array of biochemical
processes that produce three major products: S-adenosylhomocysteine (SAH), 5’deoxyadenosine (5’dADO), and 5’-methylthioadenosine (MTA). The majority of SAM is
consumed in transmethylation reactions [31], producing SAH, while 5’dADO is the
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Figure 2.1. Methionine salvage pathway in Klebsiella pneumoniae. Following the
utilization of methionine in the production of polyamines via S-adenosylmethionine
(AdoMet), 5-methylthioribose is progressively restructured into methionine by a suite of
dedicated enzymes (metK; speD, E; mtnN, K, A, B, C, D, E) [35].
product of radical-SAM reactions for vitamin biosynthesis. In the third process, SAM is
decarboxylated and subsequently loses a propylamine group to produce 5’methylthioadenosine (MTA) and the polyamines spermidine or spermine. MTA is also a
by-product of the synthesis of the signaling hormone ethylene in plants [8], and of the
quorum sensing molecule autoinducer-1 among Gram-negative bacteria [7]. In mammals,
MTA is directly converted to 5-methylthioribose-1-phosphate (MTR-1P) by the enzyme
5’-methylthioadenosine phosphorylase, whereas in plants and certain bacteria, this
process requires the concerted effort of both the 5’-methylthioadenosine/Sadenosylhomocysteine nucleosidase (MTN) and MTRK enzymes.
The pathways for the recovery of methionine following the production of MTR1P are highly similar among all organisms. Initially, MTR-1P undergoes an isomerization
to methylthioribulose-1-phosphate (MTRu-1P), and a successive dehydrogenation and
dephosphorylation to 1,2-dihydroxy-3-keto-5-methylthiopentene (DHK-MTPene). A
dioxygenase converts this to 2-keto-4-methylthiobutyrate (KMTB), which is then
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selectively transaminated to reform methionine. Many organisms catalyze these reactions
using
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This work presents a kinetic characterization of the K. pneumoniae MTRK
enzyme as well as an examination of the kinetic mechanism and MTRK substrate analog
utilization.
Materials and Methods
Bacterial strains and culture conditions. K. pneumoniae ATCC strain 43816
was used for gene amplification. Protein induction and purification were performed in E.
coli BL21 (Invitrogen) cells. All growth was performed in Luria-Bertani media at 37°C
with shaking at 225 rpm.
Chemicals and substrates. 5’-deoxy-5’-methylthioadenosine (MTA), Sribosylhomocysteine (SRH), 5-deoxyribose (5-dRIB), phosphoenolpyruvate (PEP),
dithiothreitol (DTT), and lactate dehydrogenase/ pyruvate kinase were purchased from
Sigma. Nicotinamide adenine dinucleotide (NADH) was purchased from Acros Organics,
and magnesium chloride was acquired through J.T. Baker Chemical Co. MTR and MTR
analogs were provided by Dr. Michael Riscoe (OHSU). MTR-1P was prepared in lab
through enzymatic reactions. In short, to a 2mL solution of 1mM MTA and 0.3M sodium
phosphate of pH=7, 7µg recombinant human MTA phosphorylase (previously purified in
lab) was added and allowed to react at room temperature over 1.5 hours. The solution
was then centrifuged through a Merck Millipore 3000 NMWL centrifuge filter, and the
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flow-through collected. Complete conversion of reactant was verified by the loss of
activity as a substrate for MTN enzyme (previously purified in lab).
Gene cloning. The MTRK gene sequence was amplified by whole-cell PCR using
the primer pair MTRKF (5’- GAATTCATGTCGCAATACCATACCTT – 3’) and
MTRKR (5’ – GCGGCCGCTCAGCTGTACTGGCGTACCC - 3’), and the PCR product
was digested and ligated into poly-His-encoding pPROEX HTA plasmid (Invitrogen) at
the EcoR1/Not1 digest sites. The plasmid was transformed into chemically competent E.
coli One Shot® TOP10 cells and purified using the GeneJET Plasmid Miniprep Kit
(ThermoFisher). Insert orientation was confirmed by PCR and sequencing (VA DNA
Sequencing Core Facility) and the plasmid was transformed into E. coli BL21 cells
(Invitrogen) and subsequently grown under ampicillin selection.
Protein purification. 500mL LB were inoculated with the plasmid-bearing strain
and grown to an OD600 of 0.4. Protein expression was induced with 0.5mM IPTG and the
cells were then grown overnight. Cells were centrifuged at 5000xG for 15 minutes,
washed once in 50mL PBS, centrifuged again and the pellet was lysed with 3mL BPER®
reagent over 15 minutes at room temperature with frequent vortexing. Lysate was then
centrifuged again and the supernatant was added to 3mL cobalt HisPur™ resin and set to
agitate at 4°C overnight. Column elutions were performed by centrifugation at 700xG for
2 minutes, and consisted of a flow-through, three washes with 3mL wash buffer (10mM
imidazole, 50mM NaPO4, 300mM NaCl, pH= 7.4), and three elutions with 1.5mL
500mM elution buffer (250mM imidazole, 50mM NaPO4, 300mM NaCl, pH= 7.4).
Protein identity and purity was confirmed by 15% polyacrylamide SDS-PAGE assessed
by PageRuler Plus Prestained Protein Standard (ThermoFisher), stained with Coomassie
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Blue. The enzyme concentration was quantified by A280 (ɛ280 = 1.04 mg/mL). The final
elution from the purification procedure was used for kinetic analyses, due to highest
apparent purity, and was quantified at 500ng/µL (data not shown) before being diluted to
100ng/µL at 20% glycerol for long-term storage and use in spectrophotometric assays.
MTR kinase enzyme assay. Reaction conditions were based on a linked
spectrophotometric assay wherein ADP production is stoichiometrically linked in a oneto-one relationship with NADH oxidation [44]. In brief, assays were performed at 25°C
in 1mL total volume with 1mM PEP, 0.3mM NADH, 2mM MgCl2, 5mM DTT, 0.1M
sodium phosphate pH 7, and 14U lactate dehydrogenase (LDH)/ 11U pyruvate kinase
(PK) (purchased combined from Sigma). Reaction scheme is as follows:
1)

ATP + MTR → MTR-1P + ADP

2)

ADP + PEP → ATP + pyruvate

3)

Pyruvate + NADH → lactate + NAD+

Scheme 1

For kinetic activity determinations, the non-varied substrate was used at a
concentration approximately ten times the derived Km (200 µM for MTR, 1mM for
ATP). MTR was examined at concentrations between 1 and 200 µM and ATP between
10 and 200 µM. After addition of LDH/PK enzymes to substrates, the reaction mixture
was given 5 minutes to reach equilibrium before addition of 1 µg MTRK and enzymatic
activity was continually monitored at 340 nm on Varian Cary 50 spectrophotometer (ɛ340
= 6.22 mM-1 cm-1). Data was analyzed using GraphPad Prism 6.0 software and fit to the
Michaelis-Menten equation, where:
o

max

⁄

m

Eqn. 1
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Alternate substrate assays were performed with 1mM ATP and the MTR analog
used in lieu of MTR at a concentration of 20 µM.
Homology modeling. The crystal structure of Bacillus subtilis 2PUP (GI:
37999472) was obtained from Protein Data Bank (PDB: 4L0M). Homology modeling of
the Klebsiella pneumoniae sequence (GI: 11846464) was carried out using Maestro and
Prime (ver. 4.2) of Schrodinger Suite 2015-4 [40]. Sequence alignment of 2PUP and K.
pneumoniae was conducted using the BLAST algorithm in the structure prediction
wizard in Prime. The three-dimensional K. pneumoniae structure was modeled using the
Bacillus subtilis MTRK crystal structure (PDB: 2PUP) as the template. Using the energybased approach in Prime, Bgp and MtnN homology models were constructed as homodimers with no ligands in the active sites. The homology model was then aligned with the
Bacillus subtilis structure (PDB: 2PUP) using Schrodinger. The coordinates of ADP and
PO42- were copied into the active sites of the K. pneumoniae homology model.
Molecular docking. Grid generation and ligand docking was performed using the
Glide (ver. 6.9) [41] algorithm in Schrodinger. Grid generation using the default
parameters was performed on both of the MTRK structures, with the grid centered in the
active site and a search radius of 17 Å. Molecular docking of MTR was conducted using
the standard precision (SP) method and default parameters in Glide. Results were
visualized in Maestro and images were rendered using Pymol (ver. 1.8) [42].
Results and Discussion
Genomic analysis – Examination of the genomic region surrounding MTRK in K.
pneumoniae reveals some unexpected structural organization, as well as several putative
regulatory elements (Figure 2.2). The MTRK gene in B. subtilis has been identified as
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part of a region containing independent regulons that encode the genes for every enzyme
of the methionine salvage pathway [24]. In contrast, the K. pneumoniae MTRK gene is
adjacent only to MTR-1P isomerase (Figure 2.2). These genes are separated by a 101
base pair region and are encoded on complimentary strands. Present in the promoter
region separating MTR-1P isomerase and MTRK are multiple consensus sequences for
metR and metJ regulatory domains. These regulatory mechanisms allow differential
expression dependent on intracellular methionine availability. The palindromic nature of
these sequences allows them to potentially operate as shared regulators for the two
enzymes, though the advantage of separating these genes is hard to surmise, as they fulfill
a shared metabolic role. These met-regulatory domains account for the observed
moderation of MTRK activity following growth in methionine-rich environments [16], as
well as the increased MTRK expression noted under sulfur-starved conditions [17]. The
regulatory method stands in contrast to that used by B. subtilis, which utilizes the S-box
sequence found in Gram-positive bacteria, an element common to genes involved in
sulfur metabolism [35]. The sequence upstream of MTRK also contains a purR
regulatory sequence, establishing a link to purine metabolism. This is most likely due the
relationship of MTRK with the enzyme preceding it in the salvage pathway, MTN, which
acts as a purine nucleosidase.

36

MTR‐1P
3‐phytase isomerase

MTRK

integrase transposase

CGCGCCGCGCACCCGCAGGGTATGAATATGGTCCACCAGCAGCGC
purR

AACGTTATCCGCCGCCAGCCAGCGTTTTTCCTGCGGCAAGGCCTG
CTGGTCGAGAATAAAAAGCTGATTTTCACTCACCCGCAGGCTGGT
MTR-1P isomerase

GGTCTGTAATGTCTGCATGTCGTTAAATCCCTGTTGCGTTGTTGT
metR

metJ

metJ

ATCACATTGTGTCAGGATGGAATCCAGAAGTATAGACGTCTGAAC
metR

MTRK

GGCTTAATCAGAATTCGAGGATCGAGGCA ATG TCG CAA TAC
M
S
Q
Y
Figure 2.2. Upstream sequence for K. pneumoniae MTRK. The MTRK and MTR1P genes are adjacent but not members of an operon. Predicted regulatory sequences
determined from the consensus sequences for: metJ – AGACGTCT, metR –
TGAANNATNNTTCA and purR – ACGCAAACGTTTTCNT [36][37][38].
A multiple sequence alignment between a set of bacterial and plant MTRK genes
showed high degrees of homology, with K. pneumoniae possessing a 30-40% residue
identity to each examined sequence (Figure 2.3). Critically, the residues identified as
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------------MSQYHTFTAHDAV-------AYAQQFAGIDNPSELVSAQEVGDGNLNL
-------MGVTKTPLYETLNESSAV-------ALAVKL-GLFPSKSTLTCQEIGDGNLNY
----------MDKQVFEALSAESLPHRLGGNSALREKI-GGD--VSHWTVKEIGDGNLNL
------------MNNYE---HHMLLDVEEVKCYVTSKL-QYFQKDEVLQAEEIGDGNINY
----------MSFEEFTPLNEKSLVDYIKSTPALSSKI-GADKSDDDLVIKEVGDGNLNF
MAAAAEQQQQQQQQGFRPLDEASLVAYIKATPALAARL-GGS--LDALTIKEVGDGNLNF
---MAAAAAEQQQQGFRPLDEASLVAYIKATPALAARL-GGR--LDALTIKEVGDGNLNF
^
^
VFKVFDRQGVSRAIVKQALPYVRCVGESWPLTLDRARLEAQTLVAHYQHSPQHTVKIHHF
VFHIYDQEHDRALIIKQAVPYAKVVGESWPLTIDRARIESSALIRQGEHVPHLVPRVFYS
VFIVTGSKG--TAVVKQALPYVRLVGESWPLPLKRSFFEYHALVRQAARAPGMVPEIFFF
VFRVWNPDSGKSIIIKQADKFLRSSGRAL--DVYRNKIEAEILKLEGMLAEGFVPKVYAY
VFIVVGSSG--SLVIKQALPYIRCIGESWPMTKERAYFEATTLRKHGNLSPDHVPEVYHF
VYIVLSDAG--SVVIKQALPYIRCVGDSWPMTRERAYFEASALQKHRGLCPDHVPEVYHF
VYIVLSDAG--SLVIKQALPYIRLVGDSWPMSRERAYFEASALQKHRALCPDHVPEVYHF
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Figure 2.3. Bacterial and plant MTRK sequence alignment. Represented are
diverse sequences from K. pneumoniae, B. subtilis, R. meliloti, C. difficile, A. thaliana
and both O. sativa isotypes. Residues involved in MTR substrate specificity,
ATP/Mg2+ coordination, and with catalysis are marked above with ^, *, and +,
respectively. Alignment was performed with ClustalOmega software [33].
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comprising the binding pocket and those that participate in substrate/cofactor binding and
orientation are highly homologous [20]. This suggests a strong evolutionary conservation
of enzyme in form and function between highly disparate organisms.
Protein purification – Addition of the N-terminal poly-His selection marker
resulted in a calculated molecular weight of 48.3 kD, matching the observed weight and
holding consistent with that previously reported for the native enzyme [2]. The
recombinant protein was identified by size and the apparent purity was confirmed as
>95% by SDS-PAGE (Figure 2.4).

Figure 2.4. SDS-PAGE of purified recombinant MTRK. Lane 1: Protein molecular
weight standard. Lane 2: 2µg recombinant MTRK. The calculated molecular weight for
purified rMTRK was 48.3 kD.
Substrate kinetics assays – Results of both MTR and ATP substrate-specific data
were indicative of typical Michaelis-Menten kinetics (Figure 2.5). The enzymatic rate fell
within expected parameters, showing a specific activity of 6.2 µmol/min/mg. The
apparent Km values for both substrates were determined at near-saturating conditions for
the non-varied substrates. The Km values were demonstrated to be at physiologically
relevant concentrations of 21 and 70 µM for MTR and ATP, respectively. MTR as a
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substrate demonstrated a higher catalytic efficiency than ATP by a factor of 3.3 (Table
2.1).

Figure 2.5. Substrate velocity plots of MTRK. The substrate kinetics for MTR (left)
and ATP (right) were determined using a coupled spectrophotometric assay. The data
was fit to the Michaelis-Menten equation using GraphPad Prism 6.0 software.
The Km for MTR was in close accord with that previously reported from enzyme
purified from K. pneumoniae cellular extracts at 12.2 µM [2]. Km values from
Enterobacter aerogenes for MTR and ATP were also placed at 8.1 and 74 µM [15]. A Km
for ATP had additionally been assigned for the OsMTK1 enzyme from Oryza sativa at
184 µM [19]. The O. sativa enzyme was also reported to display a significantly slower
activity than for K. pneumoniae as well as evidence of cooperative binding, which was
not observed for the K. pneumoniae MTRK. Despite the high degree of homology
between bacterial and plant MTRK sequences, large discrepancies in activity and binding
may be possible, though this may simply be an apparent difference as only one of the two
O. sativa MTRK enzymes was kinetically profiled.
Alternate Substrate kinetics – Assays were performed under conditions identical
to prior MTR substrate kinetics assays, with MTR analogs used in lieu of MTR at 20µM
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Table 2.1.

Summary of MTRK kinetic constants
Specific Activity

kcat

Km

kcat/Km

MTR

6.2 ± 0.2 µmol/min/mg

300 ± 8 min-1

21 ± 2 µM

14.2 µM-1min-1

ATP

…

…

70 ± 10 µM

4.3 µM-1min-1

Km values represent the “apparent” Km measured at conditions with the non-varied substrate held at
near-saturating concentration

concentration and standardized to the activity of MTR. Activity was observed for many
of the substrates examined, and that of n-propylthioribose exceeded that of MTR by a
significant

margin

(Table

2.2).

The

previously

identified

substrate

of

5-

trifluoromethylthioribose showed approximately two-thirds the activity of the native
substrate, while the singly-halogenated 5-fluoromethylthioribose showed one-fifth
activity. Analogs with bulkier 5-carbon substitutions showed drastically limited activities.
β-hydroxy-5-butylthioribose had one-twentieth the native catalytic rate and para-nitro-5phenylthioribose showed no catalysis. As MTR is one of three structurally similar
products of the MTN enzyme, we examined both alternate products of MTN metabolism,
S-ribosylhomocysteine and 5-deoxyribose. Neither substrate produced any observable
catalytic activity.
Table 2.2.

Summary of the relative specific activities of MTR analogs.
Substrate

5-methylthioribose (MTR)
n-propylthioribose
5-trifluoromethylthioribose
5-fluoromethylthioribose
β-hydroxy-5-butylthioribose
p-nitro-5-phenylthioribose
S-ribosylhomocysteine
5-deoxyribose

% Activity
100
168
66
20
5
0
0
0

Specific Activity
(µmol/min/mg)
6.2
10.4
4.1
1.2
0.3
0
0
0
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The capacity of n-propylthioribose as a substrate is not entirely unexpected, as 5ethylthioribose (not tested) has been shown to be an inhibitor of microbial growth owing
to its conversion by MTRK towards the toxic molecule ethionine [27]. The rationale for
its increased activity is difficult to ascertain, as the conserved Trp74, Leu345, and Leu180
residues in the B. subtilis crystal structure were proposed to gate the 5-carbon end of the
ribose molecule in order to restrict the hydrocarbon chain length [20].
5-trifluoromethylthioribose is a previously identified substrate that is ultimately
catalyzed to toxic carbonothioic difluoride [10], and exhibited two-thirds the activity of
MTR whereas the singly halogenated 5-fluoromethylthioribose showed less activity
despite it more closely resembling the native 5-methylthio group in size. This is most
likely on account of the hydrophobic nature of saturated fluorocarbons (e.g. Teflon)
discriminating binding in favor of the trifluoro-substituted analog. Examination of βhydroxy-5-butylthioribose displayed an extremely limited degree of enzymatic activity,
most likely due to the presence of the polar hydroxyl group. Additionally, p-nitro-5phenylthioribose exhibited no catalytic activity, despite the fact that a large number of
phenyl-substituted ribose analogs have been identified as highly potent inhibitors of
MTRK and organismal growth [27]. Accordingly, it seems that MTRK possesses a
certain degree of promiscuity for substitutions at the 5’ position, with a high
discrimination towards hydrophobic groups, and with group size potentially being of
lesser importance towards binding. In addition, a computational model of the K.
pneumoniae active site incorporating MTR into the binding pocket implicates a large
degree of freedom regarding rotation of the 5-carbon groups. Though Leu345 in the B.
subtilis crystallographic structure (Leu349 for Klebsiella MTRK) was proposed to act as a
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hydrophobic component of the binding pocket, its carbonyl group presents itself towards
the binding pocket at a distance of approximately 6Å from the sulfur component of MTR
(Figure 2.6). This may help in recognition of MTR by the coordination of a water
molecule between the enzyme and substrate and serve to explain why 5-deoxyribose was
not able to be utilized as a substrate.
Kinetic mechanism determination – In order to determine the substrate reaction
order, product inhibition studies were performed with MTR-1P. The analogous assay
with ADP could not be performed due to constraints of the linked enzymatic assay.

Figure 2.6. Modeled binding site of K. pneumoniae MTRK. The region
incorporating the 5-carbon region of MTR permits a high degree of freedom regarding
group size and orientation. The carbonyl moiety of Leu349, may coordinate with the sulfur
atom of the substrate.
Double reciprocal plots of MTR-1P against both MTR and ATP substrates are
presented in Figure 2.7. The results are consistent with an ordered sequential binding
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order based on Cleland’s rules, where MTR-1P appears to be the first product released
[43].
Due to constraints of the linked-enzymatic assay utilized, the substrate binding
order could not be directly examined, however, we herein propose a binding order based
on our data’s conformity to mechanistic indications derived from protein structure and
homology. In X-ray crystallographic studies of B. subtilis MTRK [20], structures were
solved exclusively with ATP derivatives and in its unbound form. No equivalent
structures containing bound MTR could be obtained, suggesting ATP as the catalytic
initiator. Additionally, structural analysis of MTRK identified the two most closely
related proteins as being choline kinase and aminoglycoside phosphotransferase type IIIa
[20]. Both have been identified as functioning via a sequential binding mechanism with
ATP being the first substrate bound [1][32]. Structurally similar mammalian kinases such
as casein kinase and cAMP-dependent protein kinase also exhibit a sequential ordered

Figure 2.7. Double reciprocal plots of MTR-1P product inhibition. Left panel
shows MTR-1P product inhibition against MTR substrate, ● = 0, ■ = 50, ▲ = 100, ▼ =
200 µM MTR-1P. Right panel shows MTR-1P product inhibition against ATP substrate,
● = 0, ■ = 20, ▲ = 50, ▼ = 100 µM MTR-1P. Both inhibition profiles are indicative of a
mixed mode of inhibition.
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mechanism with ATP binding first [29]. Examination of the enzyme binding site would
corroborate this conclusion, as ATP appears to be placed in an occluded cleft within the
binding pocket where the clearest route to the ATP-binding pocket is through the site of
MTR binding (Figure 2.6). This would seem to necessitate an ordered sequential
mechanism with the binding of ATP occurring prior to MTR. This organization of
substrates would seem to necessitate a sequential binding mechanism in order to allow
catalysis.
Our product inhibition data is consistent with these alternate data and accordingly,
we suggest an identical mechanism for MTRK, wherein ATP binds first, followed by
MTR with MTR-1P and ADP products being released, in order (shown in Figure 2.8).
ATP

E

MTR-1P

MTR

EA

EAB

EPQ

EQ

ADP

E

Figure 2.8. Cleland line describing MTRK binding. A sequential binding order with
ATP binding first and methylthioribose-1-phosphate as the first product released.
Conclusion
MTRK is essential component of the methionine salvage pathway in the
pathogenic bacteria K. pneumoniae. The gene does not form an operon with other genes
responsible for methionine recycling, and appears to be under the regulatory control of
elements involved in both purine and methionine metabolism. The purified enzyme
displayed a specific activity of 6.2 µmol/min/mg, and the substrates MTR and ATP had
apparent Km values of 21 and 70 µM. Enzyme activity towards analogs of MTR revealed
the enzyme to favor molecules with short, hydrophobic 5-carbon substitutions, and
product inhibition studies implicate an ordered sequential reaction order. We expect this
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data can be used to design inhibitors with characteristics to perform as more potent
antibiotics against target organisms.
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CHAPTER 3: PAPER #2 – DRUG INHIBITION of Klebsiella pneumoniae 5’METHYLTHIOADENOSINE/S-ADENOSYLHOMOCYSTEINE NUCLEOSIDASE
Abstract
5’-Methylthioadenosine/S-adenosylhomocysteine nucleosidase (MTN) is an
enzyme responsible for catabolism of the three downstream products of Sadenosylmethionine dependent reactions important for cellular fitness and proliferation.
Here we present a kinetic examination of purified, recombinant MTN from the Gramnegative pathogen Klebsiella pneumoniae. For the three MTN substrates of 5’methylthioadenosine, S-adenosylhomocysteine, and 5’-deoxyadenosine, we have
established Km values of 5.8 ± 0.8, 4.7 ± 0.2 and 7.0 ± 0.4 µM, and specific activities of
15.4, 5.9, and 11.3 µmol/min/mg, respectively. The enzyme inhibitory activities were
determined for four previously described transition-state analogs and four novel nonnucleoside small molecules inhibitors. Transition-state inhibitors consistently possessed
inhibition constants in the high picomolar range, and the small molecule inhibitor Ki
values were grouped in the low micromolar range.
Introduction
S-adenosylmethionine (SAM) is a molecule with a central role in a broad array of
metabolic processes. Created by the addition of methionine to ATP, SAM is utilized in a
multitude of disparate pathways in K. pneumoniae. Predominantly, SAM is utilized as the
most common methyl group donor for the transmethylation of biomolecules such as
DNA, tRNA, proteins, carbohydrates, lipids, etc. [5]. In addition, SAM is the precursor
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for the synthesis of polyamines, the production of quorum-sensing autoinducer
molecules, and a substrate for radical-SAM enzymes responsible for the synthesis of
vitamins and cofactors such as pyrroquinoline quinone (Figure 3.1) [24][23]. The MTN
enzyme serves to deadenylate the three unique products of SAM metabolism, 5’methylthioadenosine (MTA), S-adenosylhomocysteine (SAH), and 5’-deoxyadenosine
(5’dADO). These three nucleosides all function as potent product inhibitors for their
respective enzymes [5] and the buildup of MTA is known to be toxic at high
physiological concentrations [20]. The products of MTN reactions, 5-methylthioribose
(MTR) and S-ribosylhomocysteine (SRH), are recycled to methionine by subsequent
enzyme reactions, while the fate 5-deoxyribose (5-dRIB) is still unknown.
A role for MTN in microbial virulence has been proposed in Staphylococcus
aureus where MTN gene knock-out strains failed to cause infectious mortality in mice
[3]. MTN gene knock-outs in pathogenic E. coli O157:H7 also demonstrated reduced
growth rates, cellular adhesion, biofilm formation, and Shiga toxin production [20].
These effects were reversible by vitamin supplementation, suggesting that loss of MTN
led to 5’dADO accumulation and behavioral changes due to product inhibition of SAMdependent reactions involved in vitamin synthesis.
As antibiotic resistance becomes increasingly widespread, the need for novel
treatments becomes increasingly urgent. This is of particular concern regarding the
bacterial species Klebsiella pneumoniae, which is notorious for the frequency and
expansiveness of its antibiotic resistance profile. This organism is the most common
among the carbapenem-resistant Enterobactericeae, and clinical isolates typically bear
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Figure 3.1. Central role of MTN in catabolism of the products of SAM-dependent
reactions. MTN catabolizes three distinct products of SAM metabolism. All three
substrates are product inhibitors of their formative transmethylation, SAM-radical, and
polyamine syntheses.
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multiple resistances [6][27]. The conserved utilization of MTN in many pathogenic
bacteria and numerous protozoan parasites and its absence in mammals provides an
opportunity for the development of a novel broad spectrum antimicrobial agents [5].
To date, investigations into inhibitors targeting MTN have yielded mixed results.
Some bacterial species (H. pylori, B. burgdorferi) appear to be highly sensitive to MTN
inhibitors [27][15]. Other organisms (E. coli, S. aureus, V. cholera) have their growth
unaffected by inhibitors, but display reductions in autoinducer-2 secretion and biofilm
formation [3][8][12]. Research on MTN inhibitors has largely focused on MTA analogs,
and early and late-stage transition state analogs (TSAs) [28][12][13]. Both types of
inhibitors exhibit strong binding towards E. coli MTN, with the late-stage transition state
analogs in particular displaying among the tightest known non-covalent binding
properties observed in biological systems, with some Ki values against E. coli MTN
being placed in the low femtomolar range [12].
The K. pneumoniae and E. coli MTN amino acid sequences show a greater than
90% identity and complete conservation of catalytic residues (Figure 3.2). Despite this,
previous reports have shown that the native K. pneumoniae MTN displayed a Km for the
MTA substrate that was more than 20-fold greater than that of the E. coli enzyme
E.coli
K.pneumoniae

MKIGIIGAMEEEVTLLRDKIENRQTISLGGCEIYTGQLNGTEVALLKSGIGKVAAALGAT
MKIGIIGAMEEEVTLLRDKIENRQTITIGGSEIYTGQLHGVDVALLKSGIGKVAAAMGAT

60
60

E.coli
K.pneumoniae

LLLEHCKPDVIINTGSAGGLAPTLKVGDIVVSDEARYHDADVTAFGYEYGQLPGCPAGFK
LLLERCQPDVIINTGSAGGLASTLKVGDIVVSDEARYHDADVTAFGYEYGQLPGCPAGFK

120
120

E.coli
K.pneumoniae

ADDKLIAAAEACIAELNLNAVRGLIVSGDAFINGSVGLAKIRHNFPQAIAVEMEATAIAH
ADEKLVAAAESCIKALDLNAVRGLIVSGDAFINGSVGLAKIRHNFPQAIAVEMEATAIAH

180
180

E.coli
K.pneumoniae

VCHNFNVPFVVVRAISDVADQQSHLSFDEFLAVAAKQSSLMVESLVQKLAHG
VCHNFKVPFVVVRAISDVADQQSHLSFEEFLAVAARQSTLMVENLVQNLARG

232
232

Figure 3.2. ClustalOmega alignment of E. coli and K. pneumoniae MTN
sequences. The two sequences show an identity greater than 90%, with residues
critical for substrate binding and catalysis strictly conserved and highlighted [21].
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[17][22]. This apparent diversity of substrate recognition and catalysis poses a potential
challenge for subsequent inhibitor development. In order to improve our understanding of
the K. pneumonia MTN, we have cloned the MTN gene and characterized the specific
activity and substrate kinetics of the recombinant enzyme. Finally, a series of MTN
transition-state analogs and small molecule inhibitors were tested for enzyme inhibition
to provide a framework for future drug design.
Materials and Methods
Chemicals and substrates: The transition state analogs MTD – (3R, 4S)-1-[(9deazaadenin-9-yl)methyl]-3-hydroxy-4-(methylthiomethyl)pyrrolidine; BTD – (3R,4S)4-(butylthiomethyl)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxypyrrolidine; BCX – (1S)1-(9-deazaadenin-9-yl)-1,4-dideoxy-1,4-imino-5-methylthio-D-ribitol; BCZ - (1S)-1-(9deazaadenin-9-yl)-1,4-dideoxy-1,4-imino-5-propyl-D-ribitol were kindly provided by Dr.
Vern Schramm (Albert Einstein Medical College, Bronx, NY). The non-nucleoside small
molecule inhibitors 5A - (N-(2-furylmethyl)-N’-(4-nitrophenyl)urea); 8A - 1-(4nitrophenyl)-3-[4-[4[(4-nitrophenyl) carbamoylamimino] phenoxy]phenyl]-urea; 15A - 2[2-(5,6-dimethyl-1H-benzoimidazol-2-yl)vinyl]-5,6-dimethyl-1H-benzoimidazole; 27A 3-(1,3-benzothiazol-2-yl)-1-(5-{[(1,3-benzothiazol-2-yl)carbamoyl]amino}-2methylphenyl)urea were obtained from the National Cancer Institute Developmental
Therapeutics Program.
Identification of non-nucleoside inhibitors: The small molecule inhibitors tested
here were identified based on the results of in silico screening of the NCI Diversity Set II
small molecule library against the E. coli MTN structure performed by Dr. Danny Xu
(Idaho State University, School of Pharmacy) and an enzyme analysis of the top thirty-
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three compounds (unpublished results). The four most potent inhibitors against E. coli
MTN (designated 5A, 8A, 15A, and 27A) were selected for assessment against K.
pneumoniae MTN.
MTN plasmid creation and cell transformation: The MTN gene was amplified
from Klebsiella pneumoniae (ATCC strain 43816) by whole-cell PCR using the primer
pair KPMTNF (5’–ATGAAAATTGGCATTATTGGCG-3’) and KPMTNR (5’–
GCCACGTGCCAGGTTCTGTACC- 3’). The 696 base pair product was ligated into the
C-terminal poly-His-encoding pTrcHis-TOPO plasmid (Invitrogen) according to
manufacturer’s instructions before being transformed into chemically competent E. coli
One Shot™ TOP10 cells (Invitrogen) and purified using the GeneJET Plasmid Miniprep
Kit (ThermoFisher). The purified plasmid was transformed into chemically competent E.
coli OneShot™ BL21 (DE3) cells (Invitrogen). The insertion orientation was confirmed
by PCR using the KPMTNF primer and a pTrcHis-TOPO manufacturer-provided
external reverse primer. The plasmid sequence with the gene insertion was confirmed by
sequencing services provided by GeneWIZ, Inc.
Protein expression and purification: Transformed BL21 cells were grown in
500mL LB broth at 30°C to an OD600 of 0.5, and induced with 0.5mM IPTG overnight.
Cells were harvested by centrifugation (5000 x g, 15 min), and the pellets were washed
once with PBS. The washed cell pellet was homogenized in 3mL B-PER®
(ThermoFisher) reagent for 15 minutes at room temperature. Cell debris was removed by
centrifugation (10000 x g, 25 min). The recombinant Klebsiella MTN was purified from
the clarified supernatant using 3mL cobalt HisPur™ resin (ThermoFisher) according to
manufacturer’s instructions. Briefly, the recombinant enzyme was bound to the column
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by an overnight incubation at 4ºC. Unbound material was removed by centrifugation at
700 x g for two minutes. The column was washed three times with 3mL wash buffer
(10mM imidazole, 50mM NaPO4, 300mM NaCl, pH= 7.4), and the recombinant protein
eluted with three 1.5mL volumes of elution buffer (250mM imidazole, 50mM NaPO4,
300mM NaCl, pH= 7.4). Protein quantity was assessed by Bio-Rad protein assay
performed with a bovine serum albumin standard, and the purity was confirmed by SDSPAGE using PageRuler Plus Prestained Protein Standard (ThermoFisher) and stained
with Coomassie Blue. The concentration of pure enzyme was adjusted to 70 µg/mL in
20% glycerol, and stored at -80ºC before use in spectrophotometric enzyme assays.
Enzyme activity and kinetics: Nucleosidase assays were performed as previously
described [12]. Briefly, 1mL reactions contained 100mM sodium phosphate buffer (pH
6.5), and 1-50 µM substrate (MTA, SAH, or 5’dADO) at 25°C. Reactions were initiated
by the addition of 0.7 µg of enzyme. Reaction velocities were monitored at 275nm using
a Varian Cary-50 spectrophotometer (Ԑ275 = 1.60 mM-1cm-1) and the data was fit to the
Michaelis-Menten equation with GraphPad Prism 6.0 software:
o

max

⁄

Eqn. 1

m

Inhibition assays: For assessment of TSA inhibition, reaction conditions were
performed as with kinetics assays. Transition-state analog inhibition was measured at 2500 nM in the presence of 50 µM MTA and fit to the modified equation for competitive
inhibition as previously described [12].
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⁄
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Eqn. 2

For analysis of non-nucleoside small molecule inhibitors, concentrations of 0.110 µM were used. MTA substrate concentrations were varied between 5-50 µM. Data
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was fit to the equations for competitive inhibition, noncompetitive inhibition, and mixed
inhibition using GraphPad Prism 6.0 software. Data from all four small molecules (5A,
8A, 15A, 27A) fit best to the competitive inhibition model. Subsequently, the small
molecule inhibitors were tested as described for the transition state analogs and the data
fit to the modified equation for competitive inhibition (Eqn. 2).
Results and Discussion
Enzyme purification – SDS-PAGE analysis of the purified, recombinant MTN
(with C-terminal poly-His purification sequence) showed a >95% purity and an apparent
molecular weight of 30 kD (Figure 3.3). This is in close agreement with the ProtParam
[29] calculated molecular weight of 29.7 kD, based on the amino acid sequence and prior
reports for the 26.5 kD native enzyme [17].

Figure 3.3. SDS-PAGE gel of recombinant K. pneumoniae MTN. Lane 1: Protein
molecular weight standard. Lane 2: 2µg recombinant MTN. The estimated molecular
weight for purified rMTN is 30 kD.
Substrate kinetics – All three substrates demonstrated typical Michaelis-Menten
kinetics (Figure 3.4).
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Figure 3.4. Substrate velocity plots. Data is shown for the substrates 5’methylthioadenosine (left), S-adenosylhomocysteine (middle), and 5’-deoxyadenosine
(right). All data was fit to Michaelis-Menten equation using GraphPad Prism 6.0
software.
Enzyme activity and kinetic constants for each native substrate are summarized in
Table 3.1. Specific activities for the three substrates (measured at 50 µM) ranged from
5.3 to 13.8 µmol/min per mg of enzyme. MTA was the most efficiently catalyzed
substrate, consistent with previous reports for numerous other bacterial enzymes
[22][15][8][25]. The Km values for MTA and SAH (5.8 and 4.7 µM, respectively) are in
good agreement with previously reported values of 8.1 µM and 4.3 µM for native K.
pneumoniae MTN purified from cellular extracts [17]. The Km for 5’dADO was 7 µM.
This is the first reported kinetic study for this substrate. MTN demonstrated the highest
catalytic rate (460 min-1) and efficiency (79 µM-1min-1) for MTA. The catalytic
efficiencies for SAH and 5’dADO substrates were approximately half the values obtained
for MTA.
Table 3.1.

MTA
SAH
5’dADO

Summary of MTN Kinetic Constants
Specific Activity
(µmol/min/mg)
13.8
5.3
9.8

Km
(µM)
5.8 ± 0.8
4.7 ± 0.2
7.0 ± 0.4

vmax
(nmol/min)
10.8
4.1
7.1

kcat
(min-1)
460 ± 20
174 ± 3
335 ± 7

kcat/Km
(µM-1min-1)
79
37
48
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The K. pneumoniae MTN substrate specific activities for MTA and SAH are
approximately 30-fold lower than the corresponding specific activities reported for the E.
coli enzyme (373 and 156 µmol/min per mg of enzyme, respectively) [22]. In addition, K.
pneumoniae MTN displays a fourteen-fold increase in Km for MTA relative to the E. coli
enzyme (5.8µM vs. 0.4 µM), while the Km for SAH is highly similar for the two enzymes
(4.7µM to 4.3µM for E. coli) [22]. As K. pneumoniae possesses a complete enzyme
pathway to recycle methionine from MTR while E. coli does not, the increased activity of
the E. coli enzyme most likely represents an evolutionary adaptation in order to help
maintain low intracellular concentrations of toxic MTA.
Inhibition values – Four transition-state analogs and four competitive inhibitors
identified by in silico screening were tested against K. pneumoniae MTN. Fits of the
inhibition data to the equation for competitive inhibition are provided in Appendix A. As
previously described, the TSA molecules all show discrete early and late-onset inhibition
profiles resulting from a latent conformational transition of the enzyme-inhibitor complex
[12]. Representative graphs for the late-transition state analog MT-DADMe ImmA
(MTD) are shown in Figure 3.5.
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Figure 3.5. Inhibition of MTN activity by MTD. A) Kinetic activity profiles B)
Early-onset inhibition graph C) Late-onset inhibition graph. Data was fit to the modified
equation for competitive inhibition (Eqn. 2) [12].
As expected, TSAs showed binding interactions with the enzyme that were 3-4
orders of magnitude stronger than for than the non-nucleoside inhibitors (Figure 3.6).
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MTD

BTD

Ki = 1.00 ± 0.01 Ki = 1.3 ± 0.2 nM
nM
Ki* = 0.20 ± 0.03 nM
*
Ki = 0.25 ± 0.03
nM

BCX

BCZ

Ki = 4.2 ± 0.3 nM
Ki* = 0.8 ± 0.1 nM

Ki = 1.2 ± 0.2 nM
Ki* = 0.62 ± 0.08
nM

5A

8A

15A

27A

Ki = 8.8 ± 0.5 µM

Ki = 3.5 ± 0.4 µM

Ki = 4.8 ± 0.4 µM

Ki = 1.3 ± 0.2 µM

Figure 3.6. Summary of inhibition constants. Late-stage transition-state analogs
are represented by MTD and BTD, and early-stage by BCX and BCZ. The four novel
small molecule inhibitors are shown in the second row. All transition-state analogs
demonstrated discrete early and late-onset inhibition profiles with picomolar to
Relative binding affinities of the inhibitors towards K. pneumoniae and E. coli
enzymes reflected the observed discrepancies between MTA substrate activities. In
general, the E. coli enzyme shows inhibition constants for the TSAs within the
femtomolar to picomolar range in contrast to the inhibition constants for the Klebsiella
MTN that are reported here. For the early stage (BCX, BCZ) and late stage (MTD, BTD)
TSAs, the Ki values were 10-fold, and 125 to 675-fold higher, respectively, than the
values determined against the E. coli enzyme [12]. Binding affinities of the four nonnucleoside inhibitors were also lower than the 20-600 nM Ki values observed against E.
coli MTN (unpublished data).
Previously, Gutierrez, et al. compared the Ki values of BCX and MTD to classify
MTN mediated catalysis according to early dissociative or late dissociative transition
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state models [19]. High fold increases (>40) in binding affinity for the late-stage TSA
MTD relative to the early-stage TSA BCX indicated a late dissociated transition state.
Interestingly, the disparity in K. pneumoniae MTN affinities between early-stage and
late-stage TSAs were less dramatic than previously reported [19]. Our studies show only
a 3.4-fold improved affinity for MTD relative to BCX. This is largely due to a lower
observed Ki value for BCX (0.84 nM) compared to the 45nM reported in the initial study
[19]. Our data suggests that the K. pneumoniae MTN adheres more closely to an early
dissociative transition state model that is more similar to N. meningitides and H. pylori
MTNs than to the more evolutionarily related E. coli enzyme.
Conclusion
Klebsiella pneumoniae MTN possesses a highly similar sequence identity to that
of E. coli, but demonstrates a 14-fold higher Km value for MTA and a 30-fold reduction
in specific activity relative to what is reported for the E. coli enzyme. Likewise, both
transition-state analogs and non-nucleoside small molecule inhibitors were found to have
lesser capacities for enzymatic inhibition. This highlights an unexpected degree of
variability in activity among highly homologous enzymes, which could influence the
direction of future drug design to exploit the differences between species. We also report
the identification of a new set of non-nucleoside inhibitors of MTN, which will serve as a
starting point for our goal to develop MTN inhibitors that will circumvent the
inconsistent effects on cellular behavior observed for the otherwise potent transition state
analog inhibitors.
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CHAPTER 4: PAPER #3 – INFLUENCE OF MTA/SAH NUCLEOSIDASE ACTIVITY
ON BACTERIAL GROWTH AND VIRULENCE FACTOR GENE EXPRESSION
Abstract
The

enzyme

5’methylthioadenosine/S-adenosylhomocysteine

nucleosidase

(MTN) is widely utilized among bacterial species and is involved in a diverse set of
metabolic pathways. Investigations of drugs targeting this enzyme have identified strong
enzymatic inhibitors that have shown disproportionately weak effects when used as
therapeutics against most bacterial organisms. We present here an examination of the
effects of transition state analog and novel non-nucleoside MTN inhibitors against the
pathogenic bacteria Klebsiella pneumoniae. These inhibitors showed pleiotropic effects
on cell growth, with members of both inhibitors types capable of inducing either growth
deficiencies or enhanced growth rates. Neither of the two classes of MTN inhibitors were
able to cause significant alterations in biofilm formation. Lysates of cells treated with
TSA inhibitors had no observed alterations in MTN activity, but appear to display an
increase in intracellular MTN concentration. K. pneumoniae treated with a TSA inhibitor
showed upregulation of two siderophore genes and downregulation of a matrix binding
protein. A supplemental examination of gene expression in an MTN gene knock-out in
enteropathogenic E. coli O157:H7 showed significantly decreased expression in both
Shiga-like toxins, hemolysin, and a component of type 3 secretory system relative to the
wildtype strain. The results of these studies suggest antibiotics targeting MTN are
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capable of producing effects on cellular proliferation and the expression of different
virulence-associated genes in Klebsiella.
Introduction
Klebsiella pneumoniae is Gram-negative bacterium best known for its role as a
nosocomial pathogen. K. pneumoniae is currently recognized as one of the eight most
severe hospital-associated infectious agents [1]. As a pathogen, K. pneumoniae is notable
for the breadth of antibiotic resistance genes found in clinically isolated strains. K.
pneumoniae is the most common Carbapenem-resistant Enterobactericeae (CRE), and
was the origin for both Klebsiella pneumoniae carbapenemase (KPC) and New-Delhi
metallo-β-lactamase resistance genes [2][3]. Infectious strains of this organism typically
carry multiple extended-spectrum β-lactamases and carbapenemases, providing a
significant challenge for effective treatment [4]. This combination of drug resistances has
resulted in outbreaks with mortality rates that exceed 50% [5].
The

5’methylthioadenosine/S-adenosylhomocysteine

nucleosidase

(MTN)

enzyme is responsible for the hydrolytic breakdown of three distinct products of SAMdependent metabolic pathways in many bacterial species. These substrates are: 5’methylthioadenosine (MTA), S-adenosylhomocysteine (SAH), and 5’deoxyadenosine
(5’dADO). Apart from the degradation of the toxic molecules MTA and SAH [6], MTN
is additionally involved in the production of multiple metabolites important for cellular
fitness. Metabolic processes expected to be impacted by the disruption of MTN activity
include: methylations, polyamine synthesis, autoinducer production, purine and
methionine salvage, and the synthesis of vitamins used in central carbon metabolism [7].
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Transition state analog inhibitors of the MTN enzyme have displayed binding
properties that are among the strongest non-covalent interactions observed in biological
systems [8]. These inhibitors have shown potent bactericidal activity against the purine
auxotrophs Helicobacter pylori and Borrelia burgdorferi [9][10]. However, applications
of TSA inhibitors against E. coli and V. cholerae did not impact growth, and instead
caused reductions in biofilms and autoinducer-2 production [11]. MTN gene knock-outs
performed in Staphyloccocus aureus, Neisseria miningitidis, and Escherichia coli
O157:H7 have implicated the enzyme to be involved more strongly with virulenceassociated behavior than with cellular growth and fitness [12][13][14].
Materials and Methods
Strains and growth conditions – K. pneumoniae (ATCC strain 43816) was grown
in minimal media [15] modified to substitute chloride salts for sulfates. Briefly, minimal
media contains: 25 mM NH4Cl, 35mM glucose, 1.5 mM KCl, 0.4 mM MgCl, 0.045 mM
NaCl, 0.025 mM FeCl, 0.025 µg/mL thiamine, 66.6 mM sodium phosphate, 5x10-7 M
CaCl2, 5x10-8 M CoCl2, 10-7 M MnCl2, 5x10-7 M HBO3, 10-8 M ZnCl2, 10-8 M CuCO3,
5x10-9 M (NH4)6Mo7O24, pH 7.4. The media was supplemented with 100µM MTA as a
sulfur source. E. coli O157:H7 strains (ATCC 43894) were grown in Davis minimal
media supplemented with 0.4% glucose, and either 25 µg/mL chloramphenicol (for MTN
knock-out) or 50 µg/mL ampicillin + 25 µg/mL chloramphenicol (MTN knock-in).
Inhibitors - The transition state analogs MTD – (3R, 4S)-1-[(9-deazaadenin-9yl)methyl]-3-hydroxy-4-(methylthiomethyl)pyrrolidine; BCX – (1S)-1-(9-deazaadenin-9yl)-1,4-dideoxy-1,4-imino-5-methylthio-D-ribitol; BCZ - (1S)-1-(9-deazaadenin-9-yl)1,4-dideoxy-1,4-imino-5-propyl-D-ribitol were kindly provided by Dr. Vern Schramm
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(Albert Einstein Medical College, Bronx, NY). The non-nucleoside small molecule
inhibitors 5A - (N-(2-furylmethyl)-N’-(4-nitrophenyl)urea); 8A - 1-(4-nitrophenyl)-3-[4[4[(4-nitrophenyl) carbamoylamimino] phenoxy]phenyl]-urea; 15A - 2-[2-(5,6-dimethyl1H-benzoimidazol-2-yl)vinyl]-5,6-dimethyl-1H-benzoimidazole;
benzothiazol-2-yl)

-1

-(5-

{[(1,3-benzothiazol

2-yl)

27A

carbamoyl]

-

3-(1,3amino}-2-

methylphenyl)urea were obtained from the National Cancer Institute Developmental
Therapeutics Program.
Growth assays – K. pneumoniae cells were grown overnight in MTA
supplemented minimal media. Cells were then diluted 1:5000 into fresh minimal media
and 20µL was used to inoculate 160µL of media in the wells of Thermo Scientific®
polystyrene 96-well plates. A 20µL volume of dissolved drug (or solvent control) was
added to each well to achieve 10µM total drug concentration. Solubility complications
required the non-nucleoside drugs to be dissolved in DMSO, therefore the volume of
drug used was limited to 1% of the total culture volume to minimize inherent toxic
effects, and a corresponding DMSO control was performed. Growth was monitored by
hourly OD600 readings using a BioTek SynergyHT multiwell plate reader. All trials were
performed in triplicate using a minimum of three replicates per drug.
Biofilm assays – Biofilms were grown in 96-well plates that were inoculated in an
identical fashion to the cell growth assays. The cells were allowed to grow without
shaking at 30ºC over 72 hours. The cells were aspirated, and the wells washed three times
with PBS before being fixed in 250µL 1% paraformaldehyde in PBS for 1 hour at 4°C.
The wells were then washed twice with water, and stained with 250µL 0.1% crystal
violet for 15 minutes at room temperature. Excess dye was removed with four washes
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with water and the biofilm-bound crystal violet was solubilized using 250µL of a 20:80
mixture of acetone:ethanol for 10 minutes with gentle shaking. The absorbance of
extracted crystal violet was measured at 595nm using a SynergyHT multiwell plate
reader.
Intracellular MTN activity – K. pneumoniae cells were grown overnight in 10mL
sulfate-free minimal media supplemented with 100μM MTA and BCZ (MTN inhibitor)
at concentrations of 0, 5, 10, 20 and 50μM. The cells were collected by centrifugation
(10,000 x g, 15 min) and the cell pellets washed three times with PBS. Cells were lysed
in 3mL B-PER® lysis reagent (ThermoFisher) over 15 minutes at room temperature with
frequent vortexing. The cell debris was removed by centrifugation (10,000 x g, 25 min)
and the clarified supernatants were collected. The supernatant protein concentration was
estimated by absorbance at 280 nm (A0.1% = 1.0 mg/mL) and equivalent quantities of
protein were assayed for MTN specific activity using a UV spectrophotometric assay as
described by Singh, et al. [8].
Immunoblotting – Drug-treated cell lysates were electrophoresed on 15% SDSpolyacrylamide gels. Replicate gels were stained using Coomassie Blue dye and imaged,
or electroblotted onto PVDF membranes at 120V for two hours. For immunoblot analysis
the membrane was blocked overnight with 1% nonfat dry milk in PBS + 0.1% Tween 20
(PBST). The membrane was then washed three times with PBST and incubated for 30
minutes with of mouse α-MTN antibody (1:500 dilution in 1% nonfat dry milk in PBST).
The membrane was washed twice with PBST, and the primary antibody detected by
incubation for 30 minutes with goat α-mouse HRP (1:1000 dilution in PBST). The
membrane was washed three more times with PBST and chemiluminescence was
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detected using 1mL SuperSignal™ ELISA Femto Substrate (ThermoFisher) with a
FluorChem™ E imager (Protein Simple).
Autoinducer Assays – K. pneumoniae cultures were grown in AB media [16] to
early stationary phase (OD600 = 0.8) and the cells were harvested by centrifugation
(10,000 x g, 20 min). The clarified supernatants were collected and filter sterilized using
0.22 micron syringe filters. AI-2 dependent bioluminescence was measured using opaque
96-well plates containing 180µL of a 1:5000 dilution of V. harveyi (BB 170) in AB
media. Experiments were initiated by the addition of 20µL of Klebsiella culture
supernatant and the plates were incubated at 30ºC. Luminescence readings were taken
hourly using a BioTek SynergyHT multiwell plate reader over 24 hours. Relative
bioluminescence was calculated at 12 hours post-inoculation as this time represented a
maximal response for the positive control V. harveyi (BB120) strain supernatant, and
luminescence values are presented as the ratio of luminescence to that of the BB120
strain.
qRT-PCR – Cellular RNA was extracted from either K. pneumoniae (ATCC
43816) or E. coli (ATCC 43894) cells grown to late log phase in minimal media (OD600 =
0.8) using the Qiagen RNEasy Miniprep Kit according to manufacturer’s instructions,
with the inclusion of the optional DNase incubation step. Purified RNA was quantified
using a NanoDrop™ (ThermoFisher). The sample RNA concentrations were equalized to
100 ng/µL with RNase-free water. The primers used in the qRT-PCR assays are listed in
Table 4.1 and Table 4.2. A 16S rRNA internal standard was used as a control. Primer
amplification was confirmed against genomic DNA by visualization on 2% agarose gels
stained with ethidium bromide. The qRT-PCR reactions were performed using a Verso 1-
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Step qRT-PCR ROX Kit (ThermoFisher), 0.1µg template RNA, 50 pmol forward and
reverse primers, and amplified with a Lightcycler® 96 (Roche). The thermocycler
program consisted of a 15 minute preincubation at 95ºC followed by 40 cycles of 95ºC
(15 seconds) 55ºC (20 seconds) and 72ºC (50 seconds). The experiment was conducted
twice with all reactions performed in triplicate.
Table 4.1.

Klebsiella pneumoniae virulence gene primers.

Gene

Protein

Sequence

K2

Capsule component

fimH-1

Type 1 pili

mrkD

Type 3 pili

ycfM

Fibronectin adhesin

Kfu

Iron channel

entB

Siderophore

rmpA

Capsule component

Irp-2

Siderophore

ybtS

Siderophore

fyuA

Iron channel

pfs

MTN

16S
rRNA

Internal control

F: 5’-CAACCATGGTGGTCGATTAG -3’
R: 5’- TGGTAGCCATATCCCTTTGG -3’
F: 5’- ATGAACGCCTGGTCTTTTGC -3’
R: 5’- AGCTGAACGCCTATCCCCTG -3’
F: 5’- ACACCACCAACTATTCCCTC -3’
R: 5’- TGGAACCCACATCGACATTC -3’
F: 5’- ATCAGCAGTCGGGTCAGC -3’
R: 5’- CTTCTCCAGCATTCAGCG -3’
F: 5’- GGCCTTTGTCCAGAGCTACG -3’
R: 5’- TCTGGCGCAGAGAATGCCAG -3’
F: 5’- ATTTCCTCAACTTCTGGGGC -3’
R: 5’- TATCGCGCATGAAAGCATCG -3’
F: 5’- GGTCTAAAGCAGTTAACTGGAC -3’
R: 5’- CCTTATGTACCCTTTACAGCC -3’
F: 5’- CTCAGGATTCGCTGTTACCGG -3’
R: 5’- TTCGGTCATGTTCGGCCAGG -3’
F: 5’- ACATCTGGCGTTACCAGAGG -3’
R: 5’- AGTGGTGCGTTCTGCGTCG -3’
F: 5’- ACATGATTAACCCCGCGACG -3’
R: 5’- AATGCCAGGTCAGGTCACTG -3’
F: 5’- TCGTCGTCTCCGATGAAGCGC -3’
R: 5’- GCGACCGCAAGGAACTCCTC -3’
F: 5’- TGGAGCATGTGGTTTAATTGGA -3’
R: 5’- TGCGGGACTTAACCCAACA -3’

Product
size (bp)
531
689
243
160
632
384
491
304
469
547
359
159
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Table 4.2.

Escherichia coli virulence gene primers.

Gene

Protein

Sequence

eaeA

Intimin

Tir

Intimin receptor

Lpf1

Long-polar fimbriae

espB

Type-3 secretion

fimA

Adhesin

ppD

Adhesin

Stx1

Shiga-like toxin 1

Stx2

Shiga-like toxin 2

hlyA

Hemolysin A

pfs

MTN

16S
rRNA

Internal control

F: 5’- CGTCACCAGAGGAATCGGAG -3’
R: 5’- TCAGTCGCGATCTCTGAACG -3’
F: 5’- TCAATGGCTTGCTGTTTGGC -3’
R: 5’- CAAAAGGCGTTGGGGAGTTG -3’
F: 5’- GGTCAATAGTCGTTTCCGTA -3’
R: 5’- GGTCGTTGATTTAGGCAAAG -3’
F: 5’- CCGATTGCCCCATACGATTC -3’
R: 5’- CTCTGGTCAAGGCTACGGAA -3’
F: 5’- GTCCCTCAGTTCTACAGCGG -3’
R: 5’- CCGCATCAATCACCGTACCT -3’
F: 5’- GCGTCATCAAAGCGGAAGAC -3’
R: 5’- GCACTCACCGACATGCTACA -3’
F: 5’- ACACTGGATGATCTCAGTGG -3’
R: 5’- CTGAATCCCCCTCCATTATG -3’
F: 5’- CCATGACAACGGACAGCAGTT -3’
R: 5’- CCTGTCAACTGAGCAGCACTTTG -3’
F: 5’- ACGATGTGGTTTATTCTGGA -3’
R: 5’- CTTCACGTGACCATACATAT -3’
F: 5’- TGGGCGATATCGTTGTCTCG -3’
R: 5’- AGCCAGGAACTCATCGAAGC -3’
F: 5’- TGGAGCATGTGGTTTAATTGGA -3’
R: 5’- TGCGGGACTTAACCCAACA -3’

Product
size (bp)
628
415
410
474
269
323
614
779
165
380
159

Results and Discussion
Growth
The effects of TSAs and small molecule non-nucleoside inhibitors (see Figure 3.6
for structures) on Klebsiella pneumoniae growth were measured under multiple media
conditions. Klebsiella pneumoniae growth in LB media and sulfate-containing minimal
media was unaffected by TSA inhibitors at concentrations up to 20µM (data not shown).
Similarly, the non-nucleoside inhibitors failed to impact growth in nutrient rich LB
media. In order to improve the observed effects of inhibitor treatment, growth assays
were performed in minimal media that contained the substrate MTA as the sole sulfur
source. Among the transition state analog inhibitors, BCZ produced only moderate delays
in reaching log-phase growth, with cultures reaching mid log-phase growth
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approximately 4-5 hours after the untreated controls (Figure 4.1). BCX treatment
accelerated growth relative to untreated cells, although the increased growth rate does not
appear to be statistically significant. Potentially, the enhanced growth could be the result
of transmethylthiolase activity that may degrade BCX and bolster the availability of

Figure 4.1. TSA inhibitor effects on K. pneumoniae growth. K. pneumoniae
cultures were incubated with 10µM of inhibitor in minimal media containing MTA as the
sulfur source. The data shows the average of three independent experiments performed in
triplicate (±SEM, n=9).
sulfur. MTD treatment caused the most significant growth defects and delayed mid logphase growth by approximately 11 hours compared to the control. MTD is a more potent
inhibitor of the MTN enzyme than BCX or BCZ (Figure 3.6), which likely accounts for
its greater effect towards cellular growth.
Among the non-nucleoside small molecule inhibitors, 8A and 15A treatments
showed modest increases in cellular growth rates, while 5A treatment produced no
observable effects (Figure 4.2). The inhibitor 27A successfully reduced the growth rate at
mid-log and late-log phase growth, and resulted in an approximately 6 hour delay for the
cultures to reach stationary phase.
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Figure 4.2. Non-nucleoside inhibitor effects on K. pneumoniae growth. K.
pneumoniae cultures were incubated with 10µM of inhibitor in minimal media containing
MTA as the sulfur source. The data shows the average of three independent experiments
performed in triplicate (±SEM, n=9).
Biofilm Formation
Treatment with TSA inhibitors failed to cause a statistically significant impact on
biofilm formation (Figure 4.3). Despite having lesser effects on planktonic growth, BCX
and BCZ appear to cause a decreased biofilm accumulation while MTD did not.

Figure 4.3. TSA inhibitor effects on biofilm formation. K. pneumoniae cultures
were incubated for 72 hours with 10µM inhibitor, and biofilm accumulation was
measured using crystal violet staining. The results are the average of three independent
experiments with drug treatments performed in triplicate (±SEM, n=9).
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Similarly, the non-nucleoside small molecule inhibitors failed to significantly
reduce the formation of biofilms in K. pneumoniae cell cultures (Figure 4.4).

Figure 4.4. Non-nucleoside inhibitor effects on biofilm formation. K. pneumoniae
cultures were incubated for 72 hours with 10µM inhibitor, and biofilm accumulation was
measured using crystal violet staining. The results are the average of three independent
experiments with drug treatments performed in triplicate (±SEM, n=9).
The weak effect of MTN inhibitors on biofilm accumulation was not entirely
unexpected. Although biofilms deposition has been found to be under partial control by
autoinducer-mediated quorum sensing in certain bacteria [17][18], a luxS mutant of K.
pneumoniae incapable of autoinducer-2 production showed defects only in the structure
of microcolonies during the initial stages of biofilm development (less than 40 hours)
[19].
Intracellular MTN
Lysates of MTN inhibitor-treated K. pneumoniae did not exhibit differences in
MTN specific activities relative to the untreated control (Table 4.3). Several factors could
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Table 4.3.

MTN activity in cell lysates following inhibition with BCZ

Specific Activity
(nmol/min/mg)

Untreated

5 µM

10 µM

20 µM

50 µM

5.464

5.594

5.465

5.306

5.516

account for this observation. First, the inhibitors may not be efficiently transported into
the bacterial cells. However, the inhibition of planktonic cell growth by MTD and BCZ
(Figure 4.1) does not support poor drug uptake as the cause for a lack of effect on specific
activity. Alternatively, the inhibitors may be degraded or the production of enzyme
upregulated to achieve a homeostatic intracellular specific activity. Western blot analysis
of cell lysates using an MTN-specific antibody suggest an apparent increase in
intracellular MTN in response to drug treatment, although the response does not appear to
be clearly dose dependent (Figure 4.5). This would suggest a regulatory mechanism to
compensate for the deficiency of nucleosidase activity in cells following drug inhibition.
Potentially, the inability to process MTA as a sulfur source would lead to a decrease in
SAM concentrations that would alleviate MetJ repression and stimulate MTN expression.
However, previous research would suggest this is not the case, as no change in MTN
specific activity under varied concentrations of exogenous methionine [20]. Indeed, an
examination of the promoter sequence of the MTN gene reveals no strong matches for the
consensus sequences associated with either methionine or purine regulatory elements
(data not shown). However, MTN is also indirectly involved in the synthesis of many
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Figure 4.5. Effect of inhibitor treatment on MTN expression. A) Coomassie
stained SDS-PAGE of cell lysates. Lane 1: 0.1 μg recombinant MTN, Lane 2: PageRuler
Plus Prestained Protein Ladder, Lane 3-7: lysates (25 µg protein/lane) from cells grown
minimal media with 0, 5, 10, 20, and 50 μM BCZ (a, b, c, d, e). B) Immunoblot of a
replicate gel using an MTN-specific antibody.
additional metabolites and a further investigation into the regulatory mechanisms
controlling the expression of MTN may elucidate the apparent genetic upregulation we
have observed.
Autoinducer-2 Production
Treatment of Klebsiella cultures with the TSA inhibitor BCZ was predicted to
result in MTN inhibition that would cause a decrease in Autoinducer-2 (AI-2) production,
as has been shown in E. coli following treatment with TSAs [11]. AI-2 is typically
assessed using a bioluminescent reporter strain of Vibrio harveyi that produces light in
response to autoinducer detection. Unexpectedly, the BCZ-treated K. pneumoniae cell
culture supernatants produced an enhanced V. harveyi bioluminescence response (Figure
4.6). A significant induction of AI-2 dependent bioluminescence was observed when
5µM or 10µM BCZ-treated culture supernatants were examined in the assay (relative to
untreated control supernatants). The reason for this response is unclear. Potentially, this
could be a result of the observed upregulation of MTN in treated cells that would
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ultimately support a greater production of AI-2. Alternatively, it is possible that inhibitorinduced changes in K. pneumoniae metabolism, capsule formation, cellular growth, or
secreted virulence factors resulted in alterations in unexamined molecules also being
presented to V. harveyi.

A reduction of harmful components in K. pneumoniae

supernatants may have resulted in conditions that served to better facilitate the growth of
V. harveyi and thereby further exaggerate the luminescence response.

*
*

Figure 4.6. Bioluminescence assays. Average relative bioluminescence response, ±
SEM, of V. harveyi BB170 scaled to values of V. harveyi BB120 supernatant positive
control. * denotes p <0.05 by student’s T-test against untreated group, n=4.
Gene Expression
Since drug treatment produced effects on cellular behavior, we examined the
potential effects of MTN inhibitor treatment on the transcriptional expression of genes
involved in virulence for K. pneumoniae. The genes examined included those involved in
mucoviscosity (K2, rmpA), cellular adhesion (fimH, mrkD, ycfM), siderophores (kfu,
entB, irp2, ybtS, fyuA) and MTN. Transcription of most K. pneumoniae virulence genes
were not strongly impacted by treatment with BCZ (Figure 4.7), though two genes related
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to iron-scavenging (entB and irp2) showed a significant upregulation in transcript levels
(1.2-fold and 3.4-fold increase, respectively). These genes are involved in the synthetic
pathways for the siderophores enterobactin (entB) and yersiniabactin (irp2). This most
probably represent a means of response to an exacerbated degree of metabolic starvation
in minimal media that the previous growth assays indicate BCZ can induce. A reduction
in transcriptional expression of the fibronectin-binding element ycfM was also observed,

Figure 4.7. BCZ-induced alterations in K. pneumoniae gene expression. Average
virulence factor expression (± SEM) represented as the change in threshold cycle relative
to untreated cells (-∆Cq). * denotes p <0.1, and ** denotes p <0.05 by 1way ANOVA,
n=6.
though with less confidence than for entB or irp2. Data for K2 and MTN were omitted,
since their transcript levels in treated and untreated cells were not significantly greater
than the negative controls. This is possibly a result of the downregulation of MTN
expression that occurs following mid-log phase [21], as the transcriptomes were
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harvested from cells during early-stationary growth. Since western-blot evidence suggests
that MTN protein expression is upregulated in drug-treated cells (Figure 4.5), we expect
the transcript levels for MTN would corroborate this observation, but the transcript levels
appear to be too low to be detected by this assay. It will be necessary to assess the
comparative gene expression from cells harvested at an earlier phase of growth in order
to better determine whether a change in MTN transcription has truly occurred.
In order to assess a stronger direct causal relationship between MTN activity and
the expression of virulence factors, three E. coli O157:H7 strains representing wildtype
(WT), MTN knock-out (KO) and MTN knock-in (KI) were also compared for the
expression of genes contributing to adhesion (lpf, eaeA, tir, ppD, fimA, espB), and for
secreted virulence factors (stx1, stx2, hlyA). Statistically significant variations in gene
expression were observed for both Shiga-like toxins (stx1, stx2), hemolysin (hly), and the
type-3 secretory system component, espB (Figure 4.7). Shiga-like 1 was 3.6-fold
decreased, and Shiga-like 2 was 2.2-fold decreased in the KO strain relative to WT. The
other secreted virulence factor, hemolysin, also displayed a 2.8-fold transcript reduction
from the WT, though with a lesser degree of confidence. Expression of espB was 2.4-fold
decreased in the KO strain. The espB protein is a vital member of the secretory structure
that enables cellular adhesion to mammalian cells. It functions by inserting the intimin
receptor (tir) into the cell membranes of target cells to allow bacterial effacement through
the intimin protein (eaeA) [22]. Through the expression of intimin and its receptor were
not affected in the KO strain relative to WT, the reduction in espB transcription would act
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Figure 4.8. Comparative gene expression in E. coli O157:H7 WT, MTN KO and
MTN KI strains. Average virulence factor expression (± SEM) represented as the
change in threshold cycle relative to untreated cells (-∆Cq). * denotes p <0.1, and **
denotes p <0.05 by 1way ANOVA, n=6.
to subvert the activity of the binding mechanism as a whole. The observed decrease in
transcriptional expression of these four genes serves to independently support the
reported deficiencies in mammalian cell binding, hemolysin activity, and Shiga-toxin
dependent Vero-cell cytotoxicity in the E. coli MTN KO strain [23]. Interestingly, the
overexpression of MTN in the KI strain appears to have caused a significant change in
the expression of Shiga-like toxin 1, and was increased 1.7-fold over the WT strain. This
would suggest that Shiga-like 1 but not Shiga-like 2 is under positive regulatory control
of MTN-dependent metabolism. This confirms the hypothesis that MTN activity plays an
important role in supporting virulence phenotypes in E. coli and is therefore a valuable
target in the search for a class of non-lethal antimicrobial agents that function by
attenuating virulence.
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Conclusion
This work serves as a partial assessment of the potency of MTN inhibitors against
Klebsiella pneumoniae growth and virulence. Cultures in modified minimal media were
susceptible to drug treatments and showed changes in proliferation without affecting
biofilm formation. Treatment with TSA inhibitors caused an apparent accumulation of
MTN in cell lysates while maintaining equal enzyme specific activities. In addition,
supernatants from cells treated with TSA inhibitors showed an increase in AI-2
dependent luminescence response compared to untreated cells, though the reason for this
is not yet understood. Drug treatments resulted in a transcriptional upregulation of two
siderophore genes and a downregulation of an adhesion protein in K. pneumoniae. As a
point of reference, E. coli O157:H7 MTN WT, KO and KI strains were also assessed for
the expression of virulence genes. Relative to WT, the KO strain showed significant
reductions in transcript levels for both Shiga-like toxins, hemolysin, and a secretory
protein that contributes to cell adhesion. MTN inhibitors have largely shown poor results
when used as antimicrobials, but our research demonstrates their potential application as
drugs that act primarily through the debilitation of virulence and not through direct
bactericidal activity.
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CHAPTER 5: CONCLUSION
The emergence and continual escalation of antibiotic resistances among
pathogenic bacteria poses a danger to human health that must be addressed. The two
bacterial enzymes MTN and MTRK provide unique opportunities for the development of
unexploited classes of chemotherapeutic agents against a diverse array of infectious
pathogens, including the important nosocomial agent Klebsiella pneumoniae.
The variety of 5-alkylthio substituted substrate analogs that were found to be
recognized by MTRK has enabled the identification of drugs that either selectively inhibit
the methionine salvage pathway or are processed into toxic intermediates (Gianotti, et al.,
1990; Tower, et al., 1991). Substrate binding and product release of the enzyme were
found to be consistent with an ordered sequential mechanism, with ATP binding first and
MTR-1P released first. An analysis of MTR analogs showed that in general, compounds
with bulky and polar 5-alkylthio substitutions were poorer substrates compared to shorter,
hydrophobic substitutions. It is also likely that the sulfur atom plays a role in substrate
acceptance, as 5’dRIB was not able to be utilized as a substrate.
MTN represents a broad-functioning enzyme that has been heavily explored as a
therapeutic target. However, the well characterized transition-state analog inhibitors of
MTN have shown highly inconsistent effects on cellular behavior and cytotoxicity. A
comparison between TSA inhibitors and an assortment of novel inhibitors derived from
in silico screening against bacterial MTN established weaker binding affinities of the
newly identified inhibitors compared to the transition-state analogs. All of the inhibitors
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examined showed lesser binding affinities towards K. pneumoniae MTN than against the
E. coli enzyme. The impact of MTN inhibitors on Klebsiella cell growth was only
measurable when the organism was cultured in minimal media that required MTN
activity to salvage sulfur. Of the four small molecule MTN inhibitors only inhibitor 27A
was potent enough to cause a decrease proliferation, which was most apparent during
mid-log and late-log phase growth. None of the small molecule inhibitors caused
significant effects on biofilm formation. Similarly, TSA inhibitors had variable impacts
towards cellular growth, biofilms, autoinducer secretion, and the transcriptional
regulation of important virulence factors. BCZ and MTD caused growth defects, but no
discernable deficiency in biofilms. Treatment with BCZ also resulted in what appeared to
be an increase in autoinducer-2 production and an upregulation in the transcription of two
siderophore genes. K. pneumoniae appears to evade strong effects from MTN inhibitors
by compensatory expression of MTN to combat enzymatic inactivation and by
upregulation of iron-scavenging molecules that may ameliorate metabolic starvation.
Although the MTN inhibitors showed strong inhibitory power against the enzyme,
more work must be done to improve their ability to exert antimicrobial effects towards
pathogens like K. pneumoniae. Using the structures of the four novel non-nucleoside
small molecule inhibitors characterized here as a jumping-off point, work is already
being undertaken to make structural modifications to improve their inhibitory strengths.
We hope that this research presented here will serve to benefit the ongoing efforts
to develop both MTRK and MTN inhibitors as a novel antibiotic agents.
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APPENDIX
MTN Inhibitor Fits to the Equation for Competitive Inhibition
The section contains the complete set of data pertaining to the MTN inhibitors
examined in Chapter 3. The four transition state analog inhibitors (MTD, BTD, BCX,
BCZ) have two discrete inhibition values. The unmarked Ki values for the TSAs
represent activity derived from initial enzyme velocities. Ki values labelled with “*”
represent activities following delayed-onset increases in the binding affinity of the
enzyme-substrate complex. The four examined non-nucleoside small molecule inhibitors
(5A, 8A, 15A, 27A) displayed no delayed-onset inhibitory activity and possess a single
Ki value. Velocities were related as a proportion of the untreated activity using a
modified form of the Michaelis-Menten equation for competitive inhibition, where:
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